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Abstract
Tumor necrosis factor-α (TNF-α) is a pro-inflammatory cytokine and its high
levels of expression in the heart leads to cardiac dysfunction in sepsis. However, the
underlying molecular mechanisms of regulating myocardial TNF-α expression are not
fully understood. The aim of this thesis was to investigate the role of Rac1 in myocardial
TNF-α expression and cardiac dysfunction during sepsis. Studies were performed using
cultured neonatal cardiomyocytes and a mouse model of endotoxemia.
I showed that lipopolysaccharides (LPS) activated Rac1 in the myocardium. To
detect the mechanisms of Rac1 activation, phosphoinositide-3 kinase (PI3K) activity was
measured. LPS activated PI3K, which was responsible for LPS-induced Rac1 activation
in cardiomyocytes. PI3K-mediated Rac1 activation increased NADPH oxidase activity,
O2- generation, and ERK1/2 phosphorylation, leading to increased TNF-α mRNA
expression in the myocardium. Moreover, the LPS-activated PI3K/Rac1/NADPH oxidase
pathway inhibited myocardial Na/K-ATPase activity. The suppression of Na/K-ATPase
activity enhanced TNF-α protein levels without any measurable effect on TNF-α mRNA
expression or stability. Furthermore, inhibition of Na/K-ATPase activity resulted in
activation of mammalian target of rapamycin (mTOR) in cardiomyocytes via Ca2+/
calmodulin-dependent protein kinases (CaMKs). mTOR activity increased LPS-induced
TNF-α protein levels without any apparent effect on TNF-α mRNA expression. Most
importantly, cardiomyocyte-specific Rac1 deletion significantly decreased myocardial
TNF-α expression and improved cardiac function during endotoxemia in vivo.
I also demonstrated that Rac1 mediated LPS-induced p21-activated kinase (PAK)
1 activation, which increased p38 and JNK1 phosphorylation and TNF-α expression in
iii

cardiomyocytes. On the other hand, LPS increased mitogen-activated protein kinase
phosphatase-1 (MKP-1) expression in the myocardium in vivo and in cultured neonatal
cardiomyocytes in vitro. Inhibition of Rac1, PAK1 and JNK1 decreased LPS-induced
myocardial MKP-1 expression. LPS-induced ERK1/2 and p38 phosphorylation was
prolonged in MKP-1-/- myocardium. Additionally, myocardial TNF-α mRNA and protein
levels were enhanced in MKP-1-/- mice compared to WT mice in endotoxemia, which
was associated with a further decrease in cardiac function.
In conclusion, PI3K-mediated Rac1 activation is required for induction of TNF-α
mRNA and protein expression in cardiomyocytes and cardiac dysfunction during
endotoxemia. Rac1 promotes TNF-α mRNA expression via NADPH oxidase/ERK1/2
and PAK1/p38 pathways. Rac1-mediated NADPH oxidase activation enhances TNF-α
protein production via Na/K-ATPase inhibition and Ca2+/CaMK-dependent mTOR
activation. On the other hand, Rac1/PAK1 pathway induces myocardial MKP-1
expression via JNK1. MKP-1 attenuates ERK1/2 and p38 activation, thus limiting
myocardial TNF-α expression and improving cardiac function in endotoxemia. These
findings provide novel insight into the signal transduction mechanisms that regulate
myocardial TNF-α expression, and may have therapeutic implications in the treatment of
sepsis.
Key words: sepsis, phosphoinositide-3 kinase, Rac1 GTPase, NADPH oxidase, Na/KATPase, mammalian target of rapamycin, p21-activated kinase 1, mitogen-activated
protein kinase phosphatase-1, tumor necrosis factor-alpha, cardiac function
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Chapter 1. Introduction
Literature Review
Portions of this chapter appear in
Zhang T, Feng Q. (2010) Nitric oxide and calcium signaling regulate myocardial tumor
necrosis factor-alpha expression and cardiac function in sepsis. Can J Physiol Pharmacol
88:92-104. Used with permission.
1.1 Sepsis and myocardial dysfunction
1.1.1

Overview of sepsis

Sepsis is induced by a systemic immune response to infection. Sepsis, severe sepsis
and septic shock represent increasingly grave stages. Sepsis is clinically identified when a
patient has met two or more of the stated criteria for systemic inflammatory response
syndrome (SIRS) and there is an evidence of infection. These criteria include body
temperature greater than 38.5°C or less than 35.0°C, heart rate greater than 90 beats/min,
respiratory rate greater than 20 breaths per minute or arterial CO2 tension less than 32
mm Hg, white blood cell count greater than 12,000/mm3 or less than 4,000/mm3 or
greater than 10% immature forms. Severe sepsis is defined as sepsis associated with
organ dysfunction, hypoperfusion or hypotension (Merx & Weber 2007). Septic shock is
defined as severe sepsis with hypotension, despite adequate fluid resuscitation, along
with the presence of abnormalities in organ perfusion (Levy et al. 2003).
The reported mortality rate in the United States is 20-30% in sepsis and 40-80% in
septic shock (Angus & Wax 2001). In Canada, over 30% of hospitalized patients die with
sepsis, compared to 18% of stroke patients and 9.1% for heart attack patients (CIHI 2007;
CIHI 2009). The incidence of sepsis and sepsis-related deaths is increasing by 1.5% per
year due to an aging population, the use of more invasive medical procedures and

2
widespread antibiotic resistance (Angus et al. 2001). This increasing incidence
continuously puts a substantial burden on health care. A recent study showed that the
total annual hospital cost of severe sepsis in the United States was approximately $16.7
billion on the basis of 751,000 cases per year with 215,000 associated deaths (Angus et
al. 2001).
1.1.2

Myocardial dysfunction during sepsis
Septic patients normally have significant cardiac morbidity. Studies have shown

that 40% to 50% of patients with prolonged septic shock develop myocardial depression,
characterized by decreased contractility and impaired myocardial compliance (Rudiger &
Singer 2007). Myocardial dysfunction during sepsis causes a high risk of developing
multi-organ failure, which is associated with a high mortality (Court et al. 2002).
Clinically, septic shock is divided into two phases: an early hyperdynamic phase
followed by a hypodynamic phase. At the hyperdynamic phase of septic shock,
vasodilation from histamine, bradykinins, serotonin, and endorphins released during the
early stages of sepsis significantly decreases total peripheral vascular resistance (Court et
al. 2002). After adequate volume resuscitation, the cardiac output is elevated and tissue
perfusion is increased. However, besides vasodilation, these vasoactive mediators also
induce a marked capillary permeability and the so called “third space” fluid loss (ascites
and pleural effusions), leading to hypovolemia. The rise in cardiac output is limited by
hypovolemia and a fall in preload due to low cardiac filling pressures. The hypodynamic
phase of septic shock is characterized by decreased cardiac output, a sign of cardiac
dysfunction, and increased peripheral vascular resistance. The hypodynamic phase occurs
between 4 and 7 hours after the injection of endotoxin into mice (Ullrich et al. 2000).
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Rodents enter the hypodynamic phase 20 hours after cecal ligation and puncture (Yang et
al. 2002).
An early hypothesis was that global myocardial ischemia results in cardiac
dysfunction in sepsis (Merx & Weber 2007). However, later findings dismissed this
theory. It has been reported that septic patients show a decreased oxygen difference
between the coronary artery and coronary sinus, and increased coronary blood flow
(Cunnion et al. 1986). Levy et al. found that septic mice exhibited reduced cardiac
performance, higher deposits of glycogen and myocardial glucose uptake while arterial
oxygen tension and myocardial perfusion are well preserved (Levy et al. 2005),
suggesting that cardiac dysfunction is not due to myocardial ischemia during sepsis.
The expression of adhesion molecules, including vascular cell adhesion molecule
(VCAM)-1 and intercellular adhesion molecule (ICAM)-1, is enhanced in coronary
endothelium and cardiomyocytes after lipopolysaccharide (LPS) stimulation (Merx &
Weber 2007). These molecules increase myocardial neutrophil accumulation. Antibody
blockade of ICAM-1 and VCAM-1 inhibits LPS-induced cardiac dysfunction. However,
neutrophil depletion in sepsis does not offer any protection of cardiac function,
suggesting that the effect of these adhesion molecules on myocardial dysfunction is
independent of neutrophil accumulation (Raeburn et al. 2002). In addition, the activities
of proapopotic caspases are increased in the myocardium in endotoxemia, but the rate of
myocardial apoptosis is too low and disproportionate to the severity of cardiac
dysfunction (Carlson et al. 2005).
A number of factors have been identified to contribute to myocardial depression in
sepsis. These factors include prostanoids, endothelin-1, nitric oxide and pro-inflammatory
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cytokines such as interleukin (IL)-1, IL-6 and tumor necrosis factor-alpha (TNF-α),
(Kumar et al. 2000). Importantly, TNF-α treatment directly depresses cardiac
contractility, implying that TNF-α plays a key role in myocardial dysfunction during
sepsis (Walley et al. 1994).

1.2 TNF-α in sepsis
1.2.1

Overview
TNF-α is a 17 kDa protein that was initially discovered as the molecule

associated with necrosis in mouse tumors. It is an important pro-inflammatory factor that
contributes to a wide range of pathologies (Meldrum 1998; Tracey & Cerami 1993).
Systemic administration of TNF-α results in manifestations that are very similar to sepsis
including hypotension, metabolic acidosis, diffuse pulmonary infiltration, pulmonary and
gastrointestinal hemorrhage, tubular necrosis and death (Tracey et al. 1986). Notably,
TNF-α impairs contractile function in cultured cardiomyocytes and isolated hearts as
well as cardiac function in intact animals (Bozkurt et al. 1998; Grandel et al. 2000; Oral
et al. 1997). The administration of TNF-α antiserum or TNF-α binding proteins improves
cardiac function in endotoxemic mice (Peng et al. 2003b) and rats (Meng et al. 1998), and
increases survival (Peng et al. 2003b). These inhibitory effects on the heart are mediated
by the autocrine, paracrine and endocrine actions of TNF-α during sepsis. To this end,
macrophages and monocytes produce TNF-α and release it to the circulation (Schlag et
al. 1991). Circulating TNF-α acts on the heart and promotes cytokine expression in
cardiomyocytes. Additionally, cardiomyocytes themselves are the predominant local
source of TNF-α in the myocardium during sepsis (Grandel et al. 2000; Kapadia et al.
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1995; Peng et al. 2003a). Significant induction of TNF-α in the myocardium in septic
rodent models supports the notion that local TNF-α is a major contributor to cardiac
dysfunction (Grandel et al. 2000).
1.2.2

LPS signaling in TNF-α expression
Endotoxins, such as LPS, are the major pathogens responsible for myocardial

dysfunction during sepsis (Natanson et al. 1989; Suffredini et al. 1989). Cardiovascular
changes mediated by LPS simulate sepsis in both animal models (Natanson et al. 1989)
and human volunteers (Kumar et al. 2005; Suffredini et al. 1989). LPS binds to LPSbinding protein (LBP), which presents LPS to CD-14, a membrane glycoprotein with a
glycosylinositol tail. With the assistance from MD-2, the LPS-LBP-CD-14 complex
activates toll-like receptor (TLR)-4, the LPS receptor. Activation of TLR-4 results in the
recruitment of myeloid differentiation factor (MyD) 88 and Toll/interleukin-1 receptor
domain-containing adaptor protein (TIRAP). Binding of MyD88 promotes association
with the interleulin-1 receptor-associated protein kinases (IRAKs), IRAK4 and IRAK1.
IRAK4 phosphorylates IRAK-1, triggering IRAK-1 kinase activity, which in turn
activates downstream signaling pathways, leading to the activation of transcription
factors such as NF-κB and production of TNF-α (Monick & Hunninghake 2003). Studies
have demonstrated that NADPH oxidase, mitogen-activated protein kinase (MAPK)
signaling and intracellular Ca2+ all contribute to LPS-induced TNF-α expression in
cardiomyocytes (Zhang & Feng 2010).
1.2.3

Cardiac effects of TNF-α
A major mechanism of TNF-α-induced myocardial dysfunction involves

disturbances of Ca2+ homeostasis. Specifically, TNF-α disrupts Ca2+ influx through L-
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type Ca2+ channels and Ca2+-induced Ca2+ release from the sarcoplasmic reticulum
(Krown et al. 1995). In addition to Ca2+ dysregulation, TNF-α also causes direct
cytotoxicity, oxidative stress, disruption of excitation-contraction coupling, upregulation
of other cardiac suppressing cytokines (e.g., IL-1β) and the induction of cardiomyocyte
apoptosis (Song et al. 2000; Zhao et al. 2006). Studies have shown that myocardial
dysfunction induced by TNF-α has two distinct phases. The early phase occurs within
minutes after TNF-α exposure. During this phase, sphingosine production is increased
and disturbs intercellular Ca2+ homeostasis. The late phase occurs hours after TNF-α
exposure. During this phase, inducible nitric oxide synthase (iNOS) expression and
cadiomyocyte apoptosis are increased. Also pyruvate dehydrogenase activity and
mitochondrial function are inhibited (Meldrum 1998). The purpose of this thesis is to
elucidate and understand the signal transduction mechanisms that regulate myocardial
TNF-α expression and cardiac dysfunction in endotoxemia.

1.3 Rac GTPases
1.3.1

Overview
Rac GTPases are low molecular weight (20-30 kDa) monomeric GTP-binding

proteins, which are a subfamily of the Ras-homologous (Rho) GTPase family (Bustelo et
al. 2007; Fritz & Kaina 2006). Rac family contains 4 members, Rac1, Rac2, Rac3 and
RhoG (Haataja et al. 1997). Rac proteins play an important role in various cellular events,
including actin cytoskeletal reorganization, transformation, proliferation, apoptosis, gene
expression, superoxide production and migration (Bustelo et al. 2007; Fritz & Kaina
2006). Rac1, Rac2 and Rac3 have similar genetic sequence with different expression
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patterns. Rac1 is ubiquitously expressed, whereas Rac2 expression is mostly restricted to
cells of hematopoietic origin and Rac3 is expressed in the brain, liver, lung and pancreas.
RhoG has the lowest sequence similarity to Rac1 and is ubiquitously expressed (Heasman
& Ridley 2008).
1.3.2

Activation of Rac GTPases
Rac GTPases act as molecular switches, cycling between active (Rac-GTP) and

inactive (Rac-GDP) forms. GTP binding and hydrolysis are facilitated by 2 major classes
of proteins, guanine nucleotide exchange factors (GEFs) and the GTPase activating
proteins (GAPs), respectively. Under basal conditions, inactive Rac localizes in the
cytosol and generally binds to a GDP dissociation inhibitor (GDI), such as ARHGDIA,
ARHGDIB and ARHGDIG. Binding with GDI maintains the Rac in a GDP-bound state
in the cytosol and also promotes Rac dissociation from the membrane. Upon stimulation
by various factors such as cytokines, Rac-GDP dissociates from its GDI. GEFs, such as
P-Rex, SWAP-70, Tiam, Pix, Sos and Vav, become activated and open the GTPase’s
nucleotide-binding site allowing the exchange of GDP for GTP on Rac proteins.
Inactivation of Rac proteins occurs through the hydrolysis of GTP to GDP by their
intrinsic GTPase activity, which is promoted by GAPs, such ARHGAP6, ARHGAP10
and CHN (Schmidt & Hall 2002) (Figure 1.1).
Phosphoinositide 3-kinase (PI3K) is one of the activators of Rac-GEFs. PI3K
phosphorylates the phosphoinositide at the 3-OH position of the inositol ring. When the
type 1 PI3Ks are activated, they use phosphatidylinositol (4,5)-diphosphate
(PtdIns(4,5)P2) as a substrate and produce the second messenger phosphatidylinositol
(3,4,5)-triphosphate (PtdIns(3,4,5)P3). PtdIns(3,4,5)P3 can bind to the pleckstrin
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Figure 1.1. Schematic of Rac signaling pathways. In resting cells, Rac-GDP is generally
bound to a GDI. Upon stimulation by various factors, Rac-GDP dissociates from GDI
and attaches to the membrane. GEFs become activated in PI3K-dependent or –
independent ways and allow the exchange of GDP for GTP on Rac. Inactivation of Rac
proteins occurs through the hydrolysis of GTP to GDP by their intrinsic GTPase activity,
which can be greatly accelerated by GAPs. Activated Rac GTPases interact with specific
effectors (IQGAP, WAVE, p67phox and PAK) which influence diverse physiological
outcomes.

9
homology (PH) domain of target proteins and then induce their membrane translocation
and/or conformational changes (Welch et al. 2003). Rac-GEFs contain tandem Dbl
homology (DH)/PH domains. Several Rac-GEFs, such as P-Rex, SWAP-70, Tiam, Pix,
Sos and Vav have been reported to be activated by PI3K (Burridge & Wennerberg 2004;
Welch et al. 2003).
Besides PI3Ks, Rac-GEFs can also be activated by PI3K-independent
mechanisms. For example, Vav consists of three regions, an N-terminal autoinhibitor
region, a central catalytic region with a DH/PH domain and a C-terminal recruitment
region. The N-terminal autoinhibitory region has a calponin homology (CH) domain and
an acidic region with conserved tyrosines. Lck- and Src-mediated Tyr174
phosphorylation disrupts the interaction between the acidic region and the DH domain,
thereby liberating the catalytic site. In addition, some GEFs are activated by common
second messengers, such as cyclic adenosine monophosphate (cAMP), Ca2+, and
diacylglycerol (DAG) (Bos et al. 2007).
1.3.3

Effectors of Rac GTPases
Activated Rac GTPases interact with specific effectors, which coordinate

activation of a multitude of signaling cascades and influence diverse physiological
outcomes. These effectors include IQ motif containing GTPase activating proteins
(IQGAPs), Wiskott–Aldrich syndrome protein with a V-domain (WAVE), p21-activated
kinases (PAKs), and p67phox (Burridge & Wennerberg 2004; Ellenbroek & Collard 2007).
IQGAP, WAVE and PAK are cytoskeletal remodeling proteins and known to regulate the
formation of lamellipodia, filopodia and microtubule which are necessary for cell
migration, adhesion and wound healing. Interaction of Rac-GTP with p67phox results in
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activation of NADPH oxidase, which is a major source of reactive oxygen species (ROS)
(Moldovan et al. 2006). Since PAKs and NADPH oxidase are key regulators of cardiac
function in physiological and pathophysiological conditions (Bendall et al. 2002; Li et al.
2002; Mohazzab et al. 1997; Sheehan et al. 2007; Xiao et al. 2002a), it is important to
understand the molecular structure, expression, functions of NADPH oxidase and PAKs
in the myocardium.
1.3.4

Rac GTPases in the heart
Rac1 and RhoG are expressed in cardiomyocytes, whereas Rac2 and Rac3 are

undetectable in the heart (Satoh et al. 2006). Numerous studies have demonstrated that
RhoG acts either upstream of or in parallel to Rac1 to mediate neurite outgrowth, cell
motility, endocytosis and immune responses (Katoh et al. 2006; Katoh & Negishi 2003;
Vigorito et al. 2004). However, the role of RhoG in regulating cardiac function has not
been elucidated.
Rac1 knockout mice are embryonic lethal due to defects in germ-layer formation
(Sugihara et al. 1998), and thus tissue specific knockouts have been widely used to study
Rac1 function (Heasman & Ridley 2008). A cardiac-specific Rac1 deletion mouse model
is now available and shows decreased NADPH oxidase activity and superoxide anion
production. Angiotensin II (AngII)-induced cardiac hypertrophy is diminished in these
mice (Satoh et al. 2006). Rac1 transgenic mice that express constitutively activated Rac1
specifically in the myocardium have been created. These transgenic mice develop cardiac
hypertrophy within weeks after birth (Sussman et al. 2000). In addition, Rac1 enhances
hyperglycemia-induced apoptosis in cardiomyocytes. The effect of Rac1 is mediated
through NADPH oxidase activation and is associated with mitochondrial ROS generation
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(Shen et al. 2009). A recent study demonstrated that LPS induces Rac1 activation, which
contributes to NADPH oxidase activity and phosphorylation of ERK1/2 and p38 MAPK,
leading to TNF-α expression in the heart (Zhu et al. 2009). The aims of my project were
to investigate the molecular mechanisms of myocardial Rac1 activation as well as
downstream effectors of Rac1 regulating TNF-α mRNA expression, protein synthesis
and cardiac dysfunction during endotoxemia.

1.4 NADPH oxidase
1.4.1

Overview
NADPH oxidase is a multi-component enzyme system that catalyzes the NADPH

dependent reduction of O2 to O2- (Babior 1999). The prototypic NADPH oxidase is
composed of membrane bound flavocytochrome b558, which consists of gp91phox (Nox2)
and p22phox (“phox” represents phagocyte oxidase), cytosolic regulatory proteins (p40phox,
p47phox and p67phox) and Rac GTPase. The catalytic core of NADPH oxidase is the
membrane-integrated flavocytochrome b558. Under basal conditions, the cytosolic
complex is separate from the membrane-bound flavocytochrome b558. Upon stimulation,
NADPH oxidase activation is triggered by the phosphorylation of the cytosolic phox
proteins and their translocation to the plasma membrane. Concomitantly, Rac is activated
and interacts with flavocytochrome b558 to form a binding partner for p67phox. The
complete assembly of NADPH oxidase components is crucial for subsequent O2−
production (Figure 1.2). Increased O2− production is known to modulate cardiomyocyte
apoptosis, inflammatory response, contractility and cardiac hypertrophy (Babior 1999;
Griendling et al. 2000).

12

Cell membrane
Rac1
GDP

p22phox

Nox2
Rac1
GTP

Rac1
GTP

p67phox

p47phox
p40phox

NADPH oxidase

NADPH

e-

O2

NADP+ + H+

O2-

Cardiac apoptosis, inflammatory
response, contractility and
hypertrophy

Figure 1.2. Schematic of NADPH oxidase signaling pathways. NADPH oxidase is
composed of membrane bound flavocytochrome b558, which consists of gp91phox (Nox2)
and p22phox, cytosolic regulatory proteins (p40phox, p47phox and p67phox) and Rac GTPase.
Upon stimulation, NADPH oxidase activation is triggered by the phosphorylation of
cytosolic phox proteins and their translocation to the plasma membrane. Concomitantly,
Rac is activated and interacts with flavocytochrome b558 to form a binding partner for
p67phox.
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There are at least six homologues of gp91phox (Nox2): Nox1, Nox3, Nox4, Nox5
and Duox1/2. Both Nox1 and Nox4 contain 6 trans-membrane domains with NADPHbinding domain in their C-terminal regions and two hemes. They form a complex with
p22phox. Nox5, Duox 1 and Duox 2 have a Ca2+-binding site, whereas Duox1 and Duox2
have an additional transmembrane and a peroxidase-like domain (Lambeth et al. 2000;
Leto & Geiszt 2006). Nox2 and Nox4 are expressed in cardiomyocytes. They exhibit
different subcellular localization and play an important role in mediating oxidative stress.
Nox2 is primarily localized on the plasma membrane, whereas Nox4 is found primarily
on intracellular membranes, mitochondria, the endoplasmic reticulum or the nucleus
(Maejima et al. 2011). Activation of Nox2 requires assembly of NADPH oxidase
components and participates in Ang II-induced cardiac hypertrophy. NOX4 produces O2and H2O2, which do not require the association with cytosolic regulatory proteins and
Rac. NOX4 also is required for pressure overload-induced cardiac hypertrophy and heart
failure (Byrne et al. 2003).
1.4.2

NADPH oxidase and myocardial TNF-α expression during endotoxemia
NADPH oxidase is a major source of O2- in the myocardium under

pathophysiological conditions. The generation of O2- cascades into multiple cardiac
effects including hypertrophy, hypertension, fibrosis, apoptosis, proliferation and
differentiation of ES cells into cardiomyogenic cell lineage (Bendall et al. 2002; Li et al.
2002; Mohazzab et al. 1997; Xiao et al. 2002a). LPS stimulation markedly increases
NADPH oxidase activity and O2- production in cardiomyocytes. NADPH oxidase
inhibitors, such as diphenyleneiodonium (DPI) and apocynin, decrease LPS-induced
TNF-α expression (Peng et al. 2005b). Additionally, both O2- production and TNF-α
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production during LPS stimulation are blunted in Nox2-/- cardiomyocytes. Furthermore,
deficiency of Nox2 also improves myocardial function in endotoxemia (Peng et al.
2005b). These studies demonstrate a key role of Nox2-containing NADPH oxidase in
myocardial TNF-α expression and cardiac dysfunction in sepsis. MAPKs are downstream
factors of Nox2-containing NADPH oxidase signaling as pharmacological inhibition of
NADPH oxidase blocked ERK1/2, p38 and JNK phosphorylation induced by LPS
stimulation (Peng et al. 2005a; b).
Interestingly, NADPH oxidase is also involved in the expression of
cyclooxygenase (COX). COX is the rate-limiting enzyme that catalyzes the oxygenation
and reduction of arachidonic acid, leading to the formation of cyclic endoperoxides and
prostaglandins (PG) including PGE2 and PGI2 (Grandel et al. 2000; Hocherl et al. 2002;
Liu et al. 1996; Peng et al. 2005a). COX has two isoforms, the constitutive COX-1 and an
inducible COX-2. The full expression of COX-2 requires NF-κB (Rhee & Hwang 2000).
Studies have shown that COX-2 is induced during sepsis and facilitates TNF-α
expression in the heart (Grandel et al. 2000; Liu et al. 1996). Therefore, it is conceivable
that upregulation of COX-2 enhances myocardial TNF-α expression and decreases
cardiac

function

during

sepsis.

Our

group

demonstrated

that

an

NADPH

oxidase/MAPK/NF-κB-dependent pathway leads to COX-2 expression in LPS-stimulated
cardiomyocytes (Peng et al. 2005a). Indeed, inhibition of either NADPH oxidase or
MAPK activity prevents both NF-κB activation and COX-2/PGE2 production induced by
LPS (Peng et al. 2005a). Thus, O2- produced from NADPH oxidase promotes LPSinduced TNF-α expression via a MAPK/NF-κB/COX-2 signaling pathway in
cardiomyocytes.
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1.5 PAKs
1.5.1

Overview

PAKs are serine-threonine protein kinases (Bosco et al. 2009) and each consists of a
kinase domain at the C-terminas and a regulatory domain at N-terminus containing a p21binding domain (PBD). The family consists of two groups. Group I PAKs, including
PAK1, PAK2 and PAK3, are activated by GTPases such as Cdc42 and Rac. These PAKs
have an autoinhibitory domain (AID) which overlaps with the PBD. The AID interacts
with the catalytic domain forming an intramolecular inhibitory conformation. This
inhibition is released when activated Cdc42 or Rac binds with the PBD and straightens
out the protein. After this conformational change, PAK autophosphorylates Thr423 (for
PAK1) in the activation loop of the kinase. Phosphorylation of this site prevents refolding
and consequent inhibition, even in the absence of GTPases. All Group I PAKs contain a
threonine at the position corresponding to Thr423 in PAK1. PAK1, PAK2 and PAK3
have different expression patterns (Bagrodia & Cerione 1999). PAK1 is mainly expressed
in the brain, muscle, heart, and spleen. PAK2 is ubiquitously expressed. PAK3 is
expressed in the brain and heart. The group II PAKs, including PAK4, PAK5 and PAK6,
have no AID and can also bind to activated Rho-GTPases. However, binding with
GTPases leads to the translocation of group II PAKs but has no apparent effect on kinase
activity (Bagrodia & Cerione 1999; Molli et al. 2009).
1.5.2

Biological effects of PAKs

PAKs are important in cell motility, survival, proliferation and gene expression.
Primarily, PAKs are considered as regulators of the actin cytoskeletal organization and
cell motility. They phosphorylate several cytoskeleton regulators, such as LIM domain
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kinase (LIMK), myosin light-chain kinase (MLCK), paxillin and filamin A, thereby
modulating actin dynamics, cytoskeleton remodeling and focal adhesion dynamics (Molli
et al. 2009). LIMK is an actin-binding kinase which phosphorylates cofilin and prevents
the depolymerization of filament. PAK activates LIMK by phosphorylation and regulates
cell motility. MLCK phosphorylates myosin light chain (MLC) and enables the myosin to
bind to the actin filament. PAK blocks MLCK activity by phosphorylation and results in
decreased stress fibers. Paxillin localizes to focal adhesions and functions as an adaptor
protein. PAK phosphorylates paxillin which promotes the binding between paxillin and G
protein-coupled receptor kinase-interactor 1 (GIT1). GIT1 forms a complex with PAKinteracting exchange factor (PIX) and PAK, and promotes cell migration, protrusion and
adhesion turnover. Filamin A is an actin-binding protein and necessary for building of the
cytoskeleton that gives structure to cells and allows them to change shape and move.
PAK1 phosphorylates filamin A and regulates actin dynamics at the leading edge of
motile cells (Molli et al. 2009).
PAKs have both pro- and anti-apoptotic functions. PAK1 improves Bcl2 activity by
phosphorylating Bad and blocking the interaction between Bcl2 and Bad (Schurmann et
al. 2000). Furthermore, PAK1 is capable of activating dynein light chain 1 (DLC1) and
subsequently prevents inactivation of Bcl-2 (Vadlamudi et al. 2004). Activated PAK4
increases cell survival through decreasing caspase activation and promoting Bad
phosphorylation (Gnesutta et al. 2001). Specifically, PAK2 shows a dual effect in
regulating cell survival and death. DNA damage and serum starvation activate caspases
which cleaves PAK-2 proteolytically, producing a constitutively active fragment, PAK2p34. Activation of PAK2 as a full-length enzyme or as a proteolytic fragment leads to
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different effects. Activation of full-length PAK2 by Rac or Cdc42 inhibits the interaction
between Bad and Bcl-2 and promotes cell survival. In contrast, activation of PAK-2p34
correlates with the induction of apoptosis (Jakobi et al. 2001).
1.5.3 PAKs in the heart
PAK1, PAK2 and PAK3 are all expressed in the myocardium. Activated PAK1
localizes to sarcomeric Z-disks, interacts with protein phosphatase 2A (PP2A), and
reduces phosphorylation of cardiac troponin I and myosin binding protein (MyBP)-C.
These posttranslational modifications influence contractility by altering Ca2+ sensitivity
(Sheehan et al. 2007). Recent studies showed that PAK1 colocalizes with both the α1Csubunit of the L-type Ca2+ channel and PP2A. Expressing constitutively active PAK1 in
adult rat ventricular myocytes decreases the time to peak shortening, rate of [Ca2+]i decay
and time of relengthening, suggesting that PAK1 modifies Ca2+ flux (Sheehan et al.
2009). Thus, PAK1 regulates cardiomyocyte contractility by facilitating the
dephosphorylation of proteins that control myofilament activity and intracellular Ca2+
flux. Buscemi et al. reported that activated PAK3 increases fiber bundle Ca2+ sensitivity
via phosphorylation of myofilament proteins (desmin, troponin I, troponin T) (Buscemi et
al. 2002). In addition, PAK has been implicated in Rac1-induced cardiac hypertrophy in
transgenic mice (Sussman et al. 2000). There is evidence that PAK regulates IL-1
expression in macrophages through activation of MAPKs (Hsu et al. 2001). An objective
of this thesis was to investigate if PAK1 plays a role in myocardial TNF-α expression and
myocardial depression in endotoxemia (Chapter 4).
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1.6 Na/K-ATPase
1.6.1

Overview
Na/K-ATPase is located in the plasma membrane and contains a catalytic α

subunit, a β subunit and a regulatory subunit, FXYD. The α-subunit has 10
transmembrane segments and contains binding sites for Na+, K+, ATP and proteins, such
as Src. The β subunit is a glycoprotein, necessary for the transfer of the entire enzyme
molecule from the endoplasmic reticulum, the site of synthesis, to the plasma membrane.
There are presently four isoforms of the α subunit (α1, α2, α3, α4) and three isoforms of
the β subunit (β1, β2, β3). Mouse hearts express α1, α2, β1 and β2, with α1 and β1 as the
major isoforms. The FXYD protein family is a family of small membrane proteins
sharing a conserved Pro-Phe-X-Tyr-Asp motif in the extracellular N-terminal domain. In
mammals, the FXYD family contains seven members: FXYD1- FXYD7 (Geering 2006).
1.6.2

Regulation of Na/K-ATPase activity
Na/K-ATPase activity is regulated by a variety of factors that affect its activation

and expression. The simplest and most straightforward determinant of this pump activity
is the concentrations of substrates. Since intracellular Na+ concentration is a critical
factor for determining the Na/K transport rate, any change in intracellular Na+ will have
an impact on its activation. Besides, this pump is also sensitive to the changes in the
intracellular ATP and extracellular K+ concentrations.
Peptide hormones and neurotransmitters regulate Na/K-ATPase expression,
translocation or endocytosis via the protein kinases (protein kinase A (PKA), PKC and
protein kinase G (PKG)), phospholipases, and phosphatases (protein phosphatases 2B,
PP2B) in a tissue specific manner (Therien & Blostein 2000). For example, in guinea-pig
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ventricular myocytes, an isoprenaline-induced increase in Na/K-ATPase current is
mediated by cAMP, which activates PKA (Gao et al. 1994). Noradrenaline analogously
increases Na/K-ATPase current via PKC (Wang et al. 1998). In addition, steroid
hormones regulate Na/K-ATPase subunit expression. For example, aldosterone stimulates
α and β subunit gene transcription and leads to an increased pump number in the cell
membrane (Therien & Blostein 2000). Recently, a novel mechanism of Na/K-ATPase
activation has been reported. Ang II inhibits myocardial Na/K-ATPase via activating
NADPH oxidase and glutathionylating the β subunit (Figtree et al. 2009).
FXYD proteins do not affect Na/K-ATPase subunit expression but change the
transport properties in a tissue-specific way (Geering 2006). FXYD1, known also as
phospholemman, is expressed in the heart and liver, and has multiple phosphorylation
sites at its cytosolic carboxyl terminus. In resting cardiomyocytes, FXYD1 binds with the
α subunit and inhibits Na/K-ATPase activity by reducing its affinity to intracellular Na+.
Upon stimulation, FXYD1 is phosphorylated by PKC and dissociates from Na/KATPase, leading to increased Na+ affinity (Bers & Despa 2006). FXYD2 and FXYD4 are
mainly expressed in kidney. FXYD2 decreases Na+ affinity of Na/K-ATPase, which
favors an efficient reabsorption of Na+ at a high cellular Na+ load. However, FXYD4
increases affinity for Na+ which allows Na+ reabsorption at low intracellular Na+
concentrations (Beguin et al. 2001). FXYD3 is detectable in the skin, colon, stomach and
uterus and apparently decreases both Na+ and K+ affinity (Crambert et al. 2005). FXYD7
is exclusively expressed in the brain and produces low K+ affinity (Beguin et al. 2002).
1.6.3

Biological effects of Na/K-ATPase
The primary function of Na/K-ATPase is to catalyze the chemical hydrolysis of
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ATP to mediate active extrusion of Na+ and intracellular accumulation of K+. In resting
cells, the ion binding sites of Na/K-ATPase are open to the inside of the cell. Once three
Na+ ions bind to the sites, the pump is phosphorylated by ATP. The phosphorylation
causes a conformational change and exposes the Na+ ions to the outside of the cells.
Since the phosphorylated form of the pump has a low affinity for Na+ ions, Na+ ions are
released. At the same time, two K+ ions bind to the binding sites which promote the
dephosphorylation of the pump. The removal of the phosphate causes another
conformational change that result in the return of the ion binding sites to the inside of the
cell. Consequently, the K+ ions are released inside the cell. Na/K-ATPase is the main ion
pump for Na+ and K+ transmembrane distribution, and therefore it plays an essential role
in the maintenance of the Na+ and K+ gradients. These gradients are needed to facilitate
transport, regulate cellular volume, and maintain the resting membrane potential.
In addition to pumping ions, Na/K-ATPase also acts as a signal transducer.
Binding of ouabain, a specific Na/K-ATPase inhibitor, with Na/K-ATPase results in the
interaction with the cytoplasmic tyrosine kinase Src directly. The Na/K-ATPase/Src
complex acts as a “binary receptor” and activates multiple downstream protein kinases
including epidermal growth factor receptor (EGFR), MAPKs and PKC (Aydemir-Koksoy
et al. 2001; Haas et al. 2000; Haas et al. 2002). These kinases affect various cellular
functions, such as gene expression, the production of ROS, the formation of tight
junctions, cell proliferation and attachment, the modification of immune responses, the
induction of polarity, ion fluxes and protein trafficking (Aydemir-Koksoy et al. 2001;
Contreras et al. 1999; Xie & Cai 2003).
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1.6.4

Na/K-ATPase in the heart
Although Na/K-ATPase is present in all cells, it also contributes to specialized

tissue functions. In cardiomyocytes, Na/K-ATPase activity is tightly coupled to the
activation of the Na+/Ca2+ exchanger (NCX), which transports one Ca2+ ion in exchange
for three Na+ ions, therefore regulating cardiac contractility (Barwe et al. 2009; Clausen
2003; James et al. 1999). Under physiological conditions, NCX is driven by the high Ca2+
transient and works in the Ca2+ extrusion mode. When Na/K-ATPase is inhibited, [Na+]i
is elevated and subsequently drives NCX in a reverse mode. Ca2+ enters the cells through
NCX, resulting in increased cellular and sarcoplasmic reticulum (SR) Ca2+
concentrations. The higher intracellular Ca2+ concentrations lead to greater Ca2+
transients and enhanced contractility.
Na/K-ATPase also participates in cardiomyocyte apoptosis and cardiac
hypertrophy (Huang et al. 1997; Sapia et al. 2010). Ouabain induces cardiomyocyte
apoptosis. This effect of ouabain is mediated by reverse mode NCX-dependent activation
of calmodulin-dependent protein kinase (CaMK) II, and is counterbalanced by the
simultaneous activation of PI3K/AKT signaling (Sapia et al. 2010). In addition, ouabain
increases hypertrophic gene expression in cultured cardiomyocytes via Ca2+/CaMKs and
PKC (Huang et al. 1997).
Na/K-ATPase activity is decreased in multiple organs during sepsis (Guzman et
al. 1995; Koksel et al. 2006; Ohmori et al. 1991). LPS markedly decreases Na/K-ATPase
activity in the lung (Guzman et al. 1995; Koksel et al. 2006) and kidney (Guzman et al.
1995; Koksel et al. 2006). Inhibition of Na/K-ATPase potentiates LPS-induced cytokine
mRNA expression, including TNF-α mRNA, in macrophages (Ohmori et al. 1991).
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However, changes in Na/K-ATPase activity in the heart during sepsis are not known. An
objective of this thesis was to determine myocardial Na/K-ATPase activity and to
investigate if Na/K-ATPase regulates myocardial TNF-α expression during endotoxemia
(Chapter 3).

1.7 Calcium signaling and TNF-α expression during endotoxemia
Calcium is an important diffusible second messenger and controls a wide variety
of intracellular processes ranging from secretion and contraction to differentiation and
apoptosis (Clapham 2007). Levels of intracellular Ca2+ are tightly regulated. Normally,
Ca2+ makes its entrance into the cytoplasm either from outside the cell through the cell
membrane via Ca2+ channels, or from internal Ca2+ storages such as the sarcoplasmic
reticulum, endoplasmic reticulum and mitochondria. Intracellular Ca2+ is removed from
the cell by transport proteins, such as plasma membrane Ca2+-ATPase and the Na+/Ca2+
exchanger. Increased intracellular Ca2+ concentrations lead to Ca2+ binding by regulatory
proteins, which control the location, amount and effect of Ca2+ influx, and turn the Ca2+
signal into a biological response. Calmodulin is considered a major transducer of Ca2+
signals (Clapham 2007). Recent studies reported that intracellular Ca2+ concentrations are
increased in LPS-stimulated macrophages and Kupffer cells leading to TNF-α production
(Letari et al. 1991; Seabra et al. 1998; Wheeler et al. 2000; Zhou et al. 2006). The
increased Ca2+ levels may be due to Ca2+ influx and release, and mediated by PLCγ
(Zhou et al. 2006). In addition, a correlation between Ca2+/calmodulin, ERK activity and
TNF-α expression is established in mononuclear cells (Mendez-Samperio et al. 2006;
Rosengart et al. 2000b). Indeed, either the chelation of releasable intracellular stores of
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Ca2+ or the inhibition of calmodulin decreased ERK1/2 phosphorylation and TNF-α
levels induced by Mycobacterium bovis infection (Mendez-Samperio et al. 2006).
Similarly, inhibition of Ca2+ /CaMK II prevented ERK1/2 activation and the TNF-α
expression in response to LPS stimulation (Rosengart et al. 2000b).
Intracellular Ca2+ levels in cardiomyocytes are mainly regulated throught L-type
Ca2+ channels and sarcoplasmic reticulum Ca2+ release channels (or ryanodine receptors,
RyRs) during depolarization, which initiates contraction. L-type Ca2+ channels are
located primarily on the sarcolemma in close proximity with the sarcoplasmic reticulum,
and generate an inward Ca2+ current during activation. Ca2+ entering through L-type Ca2+
channels locally increases Ca2+ concentration near RyRs and triggers Ca2+ release from
the sarcoplasmic reticulum (via Ca2+ induced Ca2+ release). When Ca2+ binds to troponin
C, it switches on the myofilaments and causes contraction. During relaxation and
diastolic filling, Ca2+ dissociates from troponin C, thereby turning off the contractile
machinery. Ca2+ is removed from the cytosol mainly via the sarcoplasmic reticulum Ca2+ATPase (SERCA), which takes Ca2+ back into the sarcoplasmic reticulum, and the NCX,
and to a much less extent via sarcolemmal Ca2+-ATPase and the mitochondrial Ca2+
uniporter (Bers 2000). Apart from an essential role in cardiac excitation-contraction
coupling, Ca2+ has been shown to be important in numerous physiological and
pathophysiological processes in the heart, including cardiac hypertrophy, apoptosis,
arrhythmia and heart failure as well as gene expression (Erickson & Anderson 2008; Frey
et al. 2000).
Sepsis is associated with increased myocardial TNF-α expression and cardiac
dysfunction, both of which are regulated by cardiomyocyte Ca2+ homeostasis. Recent
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studies have demonstrated that LPS increases Ca2+ transients and ERK1/2
phosphorylation, leading to TNF-α expression in cardiomyocytes and cardiac
dysfunction (Geoghegan-Morphet et al. 2007). Treatment with ERK siRNA decreased
LPS-induced ERK activity and TNF-α expression, confirming an important role of ERK
activation. Furthermore, inhibition of L-type Ca2+ channel activity by verapamil
abrogated ERK1/2 phosphorylation and TNF-α production during LPS stimulation. These
data suggest that Ca2+ signaling results in ERK activation and TNF-α expression in
cardiomyocytes during LPS stimulation (Geoghegan-Morphet et al. 2007).

1.8 Mammalian target of rapamycin
1.8.1

Overview
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase and

contains 2549 amino acids. It forms two multi-protein complexes with distinct functions,
mTOR complex (mTORC)1 and mTORC2. mTORC1 consists of 5 components: mTOR,
mammalian lethal with Sec13 protein 8 (mLST8), regulatory-associated protein of mTOR
(Raptor), DEP-domain-containing mTOR-interacting protein (Deptor) and proline rich
Akt substrate 40 kDa (PRAS40). Raptor contributes to the assembly of the complex and
substrate recruitment for mTOR. The interaction of mLST8 with mTOR stabilizes
mTOR-Raptor association. PRAS40 and Deptor are negative regulators of mTORC1
activity (Laplante & Sabatini 2009). PRAS40 binds to Raptor and inhibits mTOR kinase
activity by blocking substrate access to Raptor. Stimuli, such as insulin, cause a release of
PRAS40 from Raptor and allow substrate presentation to mTORC1 (Wang et al. 2007).
mTORC2 is comprised of six different proteins: mTOR; rapamycin-insensitive
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companion of mTOR (Rictor), protein observed with Rictor-1 (Protor-1), mammalian
stress-activated protein kinase interacting protein (mSIN1), Deptor and mLST8. Rictor
and mSIN1 build the structural foundation of mTORC2. mLST8 is necessary for
mTORC2 stability and activity. Deptor decreases mTORC2 activity (Laplante & Sabatini
2009).
1.8.2 Regulation of mTOR signalling
mTORC1 activation is regulated by the PI3K/Akt pathway, AMP-activated
protein kinase (AMPK), the tuberous sclerosis complex (TSC)1/TSC2 complex and Ca2+
(Averous & Proud 2006; Hay & Sonenberg 2004; Hoyer-Hansen et al. 2007; Lenz &
Avruch 2005). Studies have demonstrated that growth factors activate PI3K/Akt, ERK1/2
or p90 ribosmal S6 kinase 1 pathways which lead to the inhibition of TSC1/2 complex
activation. The TSC1/2 complex comprises TSC1 and TSC2 and functions as a GAP for
Rheb, a small Ras-related GTPase. Since activated Rheb directly activates mTORC1,
TSC1/2, due to its GAP activity, negatively regulates mTORC1 activity (Hay &
Sonenberg 2004; Laplante & Sabatini 2009). In energy depletion and hypoxic conditions,
AMPK is activated upon the decline of the intracellular ATP levels. Activated AMPK
phosphorylates TSC2, leading to a reduction in mTORC1 activity (Hay & Sonenberg
2004). In primary mouse neurons, glutamatergic stimulation activates mTOR in a
Ca2+/CaMK II dependent fashion (Lenz & Avruch 2005) (Figure 1.3).
On the other hand, intracellular amino acids regulate mTORC1 via TSC1/2independent mechanisms. Rag proteins are required for mTORC1 activation induced by
amino acids. Rag binds with Raptor and promotes the intracellular localization of mTOR
to a compartment that contains its activator Rheb, resulting in the activation of mTORC1
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Figure 1.3. Schematic of mTORC1 signaling pathways. mTORC1 consists of 5
components: mTOR, mLST8, Raptor, Deptor and PRAS40. PI3K, AMPK and calcium
activate mTORC1 by inhibiting TSC1/TSC2 and activating Rheb. Amino acides activate
mTORC1 through Rag. mTORC1 plays a role in regulating protein synthesis, gene
expression and autophagy via 4E-BP, p70S6K, transcription factors (NF-κB, STAT3,
SREBP1 and PPARγ ) and the ULK1/ATG13/FIP200 complex.
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(Kim et al. 2008; Sancak et al. 2008) (Figure 1.3).
The mechanisms that activate mTORC2 are not well understood. Akt, a
downstream factor of mTORC2, is phosphorylated by phosphoinositi-dedependent kinase
(PDK) 1 which recruites to the membrane and binds with PIP3 at PH domain. Since
mSIN1, the component of mTORC2, contains a C-terminal PH domain, it is possible that
mSIN1 mediates the translocation of mTORC2 to the membrane and promotes
phosphorylation of Akt (Laplante & Sabatini 2009). Further studies are required to verify
this hypothesis.
1.8.3

Biological effects of mTORC1 signalling
mTORC1 acts as a central regulator of cell survival, proliferation and metabolism

by controlling biosynthesis of proteins, lipids and organelles and autophagy (Laplante &
Sabatini 2009) (Figure 1.3). It primarily controls protein synthesis by regulating
translation. The 5’ end of all nuclear-transcribed mRNAs possess a 7 methyl guanosine
cap (m7G) which is essential in cap-dependent protein translation initiation and is
recognized by eukaryotic translation initiation factor 4E (eIF4E). eIF4E forms a complex
with eIF4G and the RNA helicase. This complex binds the 5’ cap and unwinds the
mRNA 5’-proximal secondary structure to facilitate the binding of the 40S ribosomal
subunit. The interaction between eIF4E and eIF4G is regulated by the eIF4E-binding
proteins (4E-BPs), a family of translational repressor proteins. The 4E-BPs compete with
eIF4G proteins for an overlapping binding site on eIF4E. This process is prevented by
4E-BP

phosphorylation.

mTORC1

promotes

protein

synthesis

by

directly

phosphorylating 4E-BPs which enables eIF4E to bind with eIF4G to initiate translation
(Hay & Sonenberg 2004).
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Besides 4E-BPs, activated mTORC1 can also phosphorylate protein 70 S6 kinase
(p70S6K). p70S6K promotes translation by activating the ribosomal protein S6, eIF4B,
and eukaryotic elongation factor 2 kinase (eEF2K). Activated ribosomal protein S6 is
necessary for recruitment of mRNA to ribosomes and the formation of translation
initiation complexes. eIF4B is a protein involved in unraveling the inhibitory secondary
structure in the 5’-UTRs of certain mRNAs. p70S6K phosphorylates eIF4B and promotes
its association with translation initiation complexes. Eukaryotic elongation factor 2
(eEF2) mediates the translocation step of translation elongation and is inactivated by
eEF2K. p70S6K negatively regulates eEF2K and thereby activates eEF2 (Laplante &
Sabatini 2009).
mTORC1 also controls the transcription of certain genes via transcription factors
such as NF-κB, STAT3, peroxisome proliferator-activated receptor-γ (PPARγ) and
regulatory element binding protein 1 (SREBP1). SREBP1 and PPARγ modulate gene
expression involved in lipid and cholesterol homeostasis (Kim & Chen 2004). mTORC1
regulates lipid synthesis through SREBP1 and PPARγ (Huffman et al. 2002; Kim & Chen
2004; Porstmann et al. 2008). In macrophages, mTORC1 promotes LPS-induced proinflammatory factor expression via NF-κB but inhibits IL-10 expression via STAT3
(Weichhart et al. 2008).
Autophagy is the process of self-digestion by a cell through the action of enzymes
originating within the same cell. This process is necessary for maintaining a balance
between the synthesis, degradation, and subsequent recycling of cellular products.
mTORC1 inhibits autophagy through a protein complex containing focal adhesion kinase
family-interacting protein of 200 kDa (FIP200), autophagy-related gene 13 (ATG13) and
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unc-51-like kinase 1 (ULK1). ULK1 is a mammalian serine/threonine protein kinase and
plays a key role in the initial stages of autophagy. FIP200 and ATG13 are critical for the
correct localization of ULK1 to the pre-autophagosome and the stability of ULK1
protein. mTORC1 phosphorylates and thereby represses ULK1 and ATG13, leading to
inhibition of autophagy (Ganley et al. 2009; Jung et al. 2009).
1.8.4 Biological effects of mTORC2 signaling
mTORC2 participates in cell survival, metabolism, proliferation and cytoskeleton
organization (Laplante & Sabatini 2009). Akt is a well known factor contributing to cell
survival, metabolism and proliferation. Activation of Akt requires phosphorylation at
Ser308 and Ser473 of the protein (Manning 2004). Deletion of mTORC2 components
inhibits the phosphorylation of Akt at Ser473 and activity of transcription factors
(forkhead box protein O1, FoxO1 and FoxO3α). These two transcription factors control
the expression of genes involved in cell survival, proliferation and metabolism (Guertin
et al. 2006). mTORC2 controls the actin cytoskeleton by paxillin phosphorylation,
relocalization of paxillin to focal adhesions, and the activation of Rho-GTPases (Jacinto
et al. 2004).
1.8.5

mTOR in the heart

mTOR is now considered to be an essential regulator of cardiac function, contributing
to the development of cardiac hypertrophy in physiological or pathological conditions
(Balasubramanian et al. 2009; McMullen et al. 2004; Shioi et al. 2003). In the pressureoverloaded myocardium, both mTORC1 and mTORC2 are activated. Rapamycin, an
inhibitor of mTORC1, promotes the regression of compensated hypertrophy as well as
decompensated hypertrophy, via a p70 ribosomal S6 kinase 1–dependent mechanism
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(McMullen et al. 2004; Shioi et al. 2003). Akt, the downstream mediator of mTORC2,
promotes cardiomyocyte growth and survival, which are critical events in hypertrophic
heart, supporting a role of mTORC2 signaling in hypertrophy (Balasubramanian et al.
2009). Moreover, under hypoxic conditions, inhibition of mTORC1 by everolimus
decreases infarct size and left ventricular remodeling after myocardial infarction through
enhanced autophagy in the border region of the infarct zone (Buss et al. 2009).
Recent studies have reported that LPS activates mTOR in phagocytes, bone
marrow cells (Chen et al. 2010) and HL-1 cells (Weichhart et al. 2008). However, the
effect of mTOR on pro-inflammatory factor expression is still controversial. mTOR
promotes pro-inflammatory factors (TNF-α, IL-12) in monocyte-derived dendritic cells
(Haidinger et al. 2010). On the contrary, mTOR is a negative regulator of TNF-α
production in monocytes (Weichhart et al. 2008), macrophages (Baker et al. 2009) and
HL-1 cells (Song et al. 2010). However, the role of mTOR in the heart during sepsis has
not been elucidated. An objective of this thesis was to investigate if mTOR regulates
myocardial TNF-α production during endotoxemia (Chapter 3).

1.9 Regulation of TNF-α expression by MAPKs during endotoxemia
MAPKs are a family of serine/threonine protein kinases. There are three wellcharacterized subfamilies: p38, ERK1/2 and JNK. MAPK pathways are activated by a
dual-specificity serine-threonine MAPK-kinase (MKK) that, in turn, is phosphorylated
and activated by an upstream MKK-kinase (MKKK) at two serine residues. The
phosphorylation of MAPKs leads to increased substrate accessibility and catalysis (Cobb
& Goldsmith 2000). Activated MAPKs can activate a wide range of downstream targets
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and regulate gene transcription, mRNA stability, transport and translation (Davis 1993;
Dong et al. 2002; Hazzalin & Mahadevan 2002). These signaling cascades are not only
involved in normal cellular process, but have also been implicated in the pathology of
many diseases, such as cancer, atherosclerosis, diabetes, arthritis and septic shock (Liu et
al. 2007).
1.9.1

p38
To date, five p38 isoforms have been identified: p38α, p38β, p38β2, p38γ and

p38δ. The p38α and p38β genes are ubiquitously expressed. However, p38γ and p38δ are
differentially expressed in different tissues. p38γ is synthesized mostly in skeletal muscle
and p38δ is expressed in lung, kidney, testis, pancreas and small intestine (Ono & Han
2000). The p38 pathway is known to be responsible for a multitude of cellular events,
such as proliferation, differentiation, apoptosis and inflammation (Herlaar & Brown
1999). Recently, p38 has been recognized as an important regulator of heart function in
various animal models. For example, transgenic mice with targeted activation of p38 in
cardiomyocytes have impaired systolic as well as diastolic functions of the heart (Liao et
al. 2001). p38 is activated in the myocardium during ischemia and reperfusion. Deletion
of p38α gene decreases infarct size following myocardial ischemia and reperfusion (Otsu
et al. 2003). In spontaneously hypertensive stroke-prone rats receiving a high-salt/highfat diet, myocardial p38 is activated during the development of cardiac hypertrophy and
contributes to hypertensive end-organ damage and premature mortality (Behr et al. 2001).
Moreover, evidence suggests a key role of p38 activity in myocardial TNF-α expression
and cardiac dysfunction in sepsis. For instance, LPS increases p38 phosphorylation in
primary neonatal cardiomyocytes (Peng et al. 2005a; b; Peng et al. 2003a; Peng et al.
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2003b). Pharmacological inhibition of p38 or specific down-regulation of p38α
significantly suppresses both TNF-α mRNA and protein levels in cardiomyocytes (Peng
et al. 2003b). Consistent with these in vitro studies, p38 is also activated and mediates
myocardial TNF-α expression in sepsis. Inhibition of p38 activity significantly reverses
LPS-induced left ventricular depression and decreases mortality to 65% in endotoxemia
(Peng et al. 2003b). Therefore, p38 activation plays a critical role in myocardial TNF-α
expression and myocardial depression in endotoxemia (Zhang & Feng 2010).
1.9.2

ERK1/2
Phosphorylation of ERK1 and ERK2 (p44 MAPK and p42 MAPK, respectively)

are catalyzed by MEK1/2, which in turn, are activated by Raf-1. The ERKs can
phosphorylate transcription factors, such as Elk-1, SAP1, Ets, and NF-κB, thereby
regulating expression of proteins required for a given response. Activation of ERK1/2
promotes TNF-α expression during sepsis in several types of cells including
cardiomyocytes (Peng et al. 2005a; b; Rosengart et al. 2000b). Indeed, ERK1/2 in
cardiomyocytes is phosphorylated transiently but dramatically by LPS stimulation.
Inhibition of ERK1/2 by ERK siRNA or pharmacological inhibitors (e.g., PD98059 and
U0126) abrogates TNF-α production induced by LPS (Geoghegan-Morphet et al. 2007;
Peng et al. 2005b), suggesting that ERK1/2 play an important role in TNF-α expression.
Furthermore, inhibition of ERK1/2 by U0126 decreases TNF-α production and protects
the lung from LPS-induced injury in mice (Schuh & Pahl 2009).
1.9.3

JNKs
JNKs are activated by MKK4 and MKK7. The JNK family contains three

members: JNK1, JNK2 and JNK3. JNK1 and JNK2 are expressed in the myocardium (Ip
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& Davis 1998). LPS activates JNK and increases TNF-α transcription and translation in
macrophages and monocytes (Comalada et al. 2003; Swantek et al. 1997). LPS also
increases phosphorylation of JNKs in cultured mouse neonatal cardiomyocytes (Peng et
al. 2005a; Peng et al. 2009). Unexpectedly, JNK1 activation decreases TNF-α expression
in these cells (Peng et al. 2009). Deficiency of the JNK1 gene further enhances TNF-α
expression in cardiomyocytes in response to LPS. In addition, blocking JNK1 signaling
pathway also enhances the ROS production stimulated by LPS (Peng et al. 2009), which
may be due to the increase of TNF-α levels (Garg & Aggarwal 2002). Increased ROS
production and TNF-α expression may lead to myocardial depression. Indeed, cardiac
function in JNK1-/- mice is further decreased in endotoxemia, compared with wild-type
animals (Peng et al. 2009).

These data demonstrate that JNK1 activation inhibits

myocardial TNF-α expression and improves cardiac function in endotoxemia. In
addition, deficiency in JNK1 enhances LPS-induced p38 and ERK1/2 activity (Peng et al.
2009), suggesting crosstalk among the MAPK subfamily members in cardiomyocytes
during sepsis.
1.9.4

Crosstalk among MAPKs
Crosstalk among different MAPK signaling pathways may determine the final

biological response upon stimulation and the nature of the crosstalk varies depending on
the cell types and stimuli. For example, transforming growth factor-β (TGF-β)-stimulated
ERK1/2 activation caused dephosphorylation of LPS-induced p38 in macrophages (Xiao
et al. 2002b). Conversely, activation of p38 by adenoviral expression of MKK3b
dephosphorylates MEK1/2 via phosphatase 2A in human skin fibroblasts (Junttila et al.
2008; Li et al. 2003). Additionally, sustained JNK activation due to mitogenic factors
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inhibits ERK activity in COS-7 cells (Shen et al. 2003).
In cardiac myocytes, activation of different MAPKs shows completely opposite
effects in sepsis. In this regard, activation of p38 and ERK1/2 promote TNF-α
production, while activation of JNK1 inhibits TNF-α expression during LPS stimulation
(Peng et al. 2009). Our group has shown that deficiency in JNK1 enhances LPS-induced
p38 and ERK1/2 activity and TNF-α production in myocardium, suggesting a negative
feedback of JNK1 on p38 and ERK1/2 activity (Peng et al. 2009). Interestingly, the
inhibitory effects of JNK1 are mediated by c-fos, an immediate early response gene
involved in a wide spectrum of cellular response including cell proliferation, growth and
cytokine production (Herrera & Robertson 1996; Lee et al. 2004). The expression of cfos is enhanced by LPS stimulation in the myocardium, and disrupted by an adenovirus
encoding dominant negative mutant of JNK1 and a JNK pharmacological inhibitor
(SP600125), suggesting the c-fos is downstream of JNK1 (Meng et al. 1998; Peng et al.
2009). Furthermore, deficiency of c-fos gene augmented p38 and ERK1/2 activity and
cardiac TNF-α expression. Conversely, over-expression of c-fos inhibited TNF-α
production associated with reductions in p38 and ERK1/2 activity. More importantly,
deficiency in c-fos resulted in a further damage in cardiac function during endotoxemia
(Peng et al. 2009). These results demonstrate the inhibitory effects of c-fos on p38 and
ERK1/2 activity, and TNF-α expression, leading to improvement in cardiac function
during endotoxemia. c-fos can dimerise with c-jun to form the activator protein 1 (AP-1),
which upregulates the transcription of a diverse range of genes. However, the effects of cfos in cardiac myocytes are independent of AP-1 since inhibition the formation of cfos/c-jun AP-1 complex or treatment with a decoy AP-1 oligodeoxynucleotide did not
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alter TNF-α expression (Peng et al. 2009). Therefore, the JNK1 inhibits LPS-induced
TNF-α expression through inhibition of ERK1/2 and p38 activation (Zhang & Feng
2010). This negative crosstalk is mediated by c-fos (Figure 1.4).

1.10 MAPK phosphatases
1.10.1 Overview
The strength and duration of MAPK signaling are tightly controlled in cells and
tissues. Dephosphorylation of MAPKs is the most efficient way for termination of these
pathways. Dual-specificity (tyrosine and threonine) MAPK phosphatases (MKPs) have
been shown to inactivate MAPK by dephosphorylating phosphothreonine and
phosphotyrosine residues (Liu et al. 2007).
In mammalian cells, 11 MKPs have been identified (MKP-1 – MKP-5, MKP-7,
MKPX, dual specific phosphatase 2 (DUSP2), human VH1-like PTPase-3 (HVH3),
HVH5, DUSP24) (Dickinson & Keyse 2006). According to subcellular localization and
patterns of transcriptional regulation, MKPs are divided into two groups. Group 1,
including MKP1, MKP2, HVH3 and DUSP2, is primarily localized in the nucleus.
Expression of these MKPs can be quickly induced by extracellular stimuli to negatively
controls MAPK activity. The MKPs in group 2 are localized in the cytoplasm and/or
nuclear compartments. The expression of these genes is induced at a much slower rate
compared with the genes that encode the first group of MKPs (Keyse 2000).
1.10.2 MKP-1 and TNF-α expression during endotoxemia
MKP-1, the founding member of this family, is a critical regulator of innate immune
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Figure 1.4. Crosstalk among MAPKs on regulating LPS-induced TNF-α expression in
cardiomyocytes. ERK1/2 and p38 MAPK activity enhance LPS-induced TNF-α
production, while JNK1 activity shows an inhibitory effect. This function of JNK1 is
performed by attenuating LPS-induced ERK1/2 and p38 MAPK activity via c-fos.
(Adapted from Can. J. Physiol. Pharmacol., Zhang and Feng, 2010).
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responses (Liu et al. 2007). Overexpression of MKP-1 accelerates JNK and p38
inactivation and attenuates TNF-α production in RAW264.7 macrophages in response to
LPS, indicating that MKP-1 preferentially inactivates p38 and JNK relative to ERK
(Chen et al. 2002). Consistently, MKP-1 deficiency leads to sustained activation of p38
and JNK, and enhances pro-inflammatory factor expression in LPS-treated macrophages
(Zhao et al. 2006). Furthermore, MKP-1-/- mice exhibit significantly increased serum
TNF-α, IL-1β, CC-chemokine ligand 2 (CCL2), interferon-gamma (IFN-γ) and IL-6, and
show a higher incidence of multi-organ failure and a greater mortality rate in
endotoxemia, compared with wild-type mice (Hammer et al. 2006; Salojin et al. 2006),
these findings suggest that MKP1 is an important negative regulator of MAPK and
inhibits TNF-α expression during the inflammatory response of the innate immune
system (Liu et al. 2007).
1.10.3 Regulation of MKP-1 activity
The phosphatase activity of MKP-1 is regulated by transcriptional induction and
protein stability (Liu et al. 2007). MKP-1 expression is inducible. In fibroblasts, MKP-1
induction is dependent on ERK1/2 (Brondello et al. 1997) or JNK activation (Bokemeyer
et al. 1996). PKC, Raf-1 and JNK1 are involved in MKP-1 transcriptional induction in
macrophages (Sanchez-Tillo et al. 2006; Sanchez-Tillo et al. 2007; Stawowy et al. 2003;
Valledor et al. 2000; Valledor et al. 1999). The Ras/Rac pathway is necessary for
increasing MKP-1 expression in smooth muscle cells in response to cyclic strain stress
(Li et al. 1999).
MKP-1 can be post-translationally modified via phosphorylation, which is not
necessary for MKP-1 activity, but leads to stabilization of the protein. Indeed ERK-
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induced phosphorylation of MKP1 at Serine 359 and Serine 364 increases MKP1 half-life
by two to three folds (Brondello et al. 1999). The reduced degradation results in a greater
MKP-1 accumulation and thereby greater MKP-1 activity.
1.10.4 MKP-1 in the heart
MKP-1 has been demonstrated in cardiomyocytes and regulates cardiac hypertrophy
and cardiomyocyte apoptosis (Fischer et al. 1998; Kaiser et al. 2004; Palm-Leis et al.
2004). MKP-1 is upregulated in hypertrophic hearts induced by Ang-II (Fischer et al.
1998). Overexpression of MKP-1 in cardiomyocytes significantly inhibits cyclic stretchand Ang II-induced JNK and p38 activation, and the consequent increase in protein
synthesis (Palm-Leis et al. 2004). These results indicate that MKP-1 limits the cardiac
hypertrophic response. In addition, transgenic mice overexpressing MKP-1 show
significant inhibition of baseline p38 and JNK activation in the heart. Ischemia-induced
prominent p38 phosphorylation and cardiomyocyte apoptosis are significantly inhibited
in MKP-1 transgenic mice. Consistently, MKP-1-/- mice show greater injury compared
with wild-type littermates after ischemia/reperfusion (Kaiser et al. 2004). The evidence
supports the notion that MKP-1 decreases cardiomyocyte apoptosis and cardiac injury
after ischemia/reperfusion via deactivating p38. Although MKP-1 may protect the heart
during hypertrophy and ischemia/reperfusion, the effect of MKP-1 on cardiac
dysfunction during sepsis remains unknown. One of the objectives of this study was to
elucidate the role of MKP-1 in cardiac TNF-α expression during endotoxemia (see
Chapter 4).
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1.11 Rationale and hypotheses
The induction of tumor necrosis factor-α (TNF-α) expression in cardiomyocytes
leads to myocardial depression during sepsis. However, the underlying molecular
mechanisms are not fully understood. Rac1, a small monomeric GTP-binding protein,
regulates various cellular functions, such as superoxide (O2-) production, microtubule
stability, cytoskeletal remodeling and gene transcription (Burridge & Wennerberg 2004;
Hordijk 2006). It is an essential regulator of cardiac function under physiological and
various pathological conditions (Satoh et al. 2006; Shen et al. 2009; Sussman et al. 2000).
A recent study has reported that LPS activates Rac1 in cardiomyocytes. Rac1-GTP
activates NADPH oxidase and then leads to TNF-α mRNA expression in cardiomyocytes
(Zhu et al. 2009). However the mechanisms of Rac1 activation and the downstream
signaling of Rac1 on TNF-α production and myocardial dysfunction during endotoxemia
are not fully elucidated. Thus, the overall hypothesis of this thesis was that Rac1
promotes TNF-α expression and myocardial dysfunction during endotoxemia (Figure
1.5).
PI3K is an important activator of Rac-GEFs (Welch et al. 2003). PtdIns(3,4,5)P3, a
product of PI3K, activates Rac through PtdIns(3,4,5)P3-sensitive GEFs in neutrophils and
fibroblasts (Burridge & Wennerberg 2004; Welch et al. 2003). On the other hand, Rac
can also be activated by PI3K-independent mechanisms, such as cAMP, Ca2+, DAG and
Src (Welch et al. 2003). Until now, the mechanisms of myocardial Rac1 activation in
endotoxemia are unclear. Thus the first specific hypothesis of this thesis (Chapter 2) was
that PI3K-mediated Rac1 activation is required for myocardial TNF-α expression and
cardiac dysfunction via NADPH oxidase in endotoxemia (Figure 1.5).
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Figure 1.5. Proposed hypotheses of Rac1 in regulating myocardial TNF-α expression and
cardiac dysfunction in endotoxemia. Hypothesis 1: PI3K-mediated Rac1 activation is
required for myocardial TNF-α expression and cardiac dysfunction via NADPH oxidase
in endotoxemia. Hypothesis 2: Rac1 promotes LPS-induced TNF-α production via
inhibition of Na/K-ATPase. Hypothesis 3: Rac1/PAK1 induces myocardial MKP-1
expression via JNK1 in response to LPS. It was further hypothesized that increased
MKP-1 production limits TNF-α expression and improves heart function in endotoxemia.
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Na/K-ATPase catalyzes ATP hydrolysis to actively transport Na+ out of and K+ into
cells. It is the main pathway for Na+ extrusion from the cells and therefore plays an
essential role in the regulation of intracellular Na+ concentrations, which, via the
Na+/Ca2+ exchanger, control intracellular Ca2+. Our group has reported that LPS increases
Ca2+ concentration in cardiomyocytes, which participates in TNF-α expression in these
cells. In addition, Na/K-ATPase activity is decreased in the lung (Koksel et al. 2006) and
kidney (Guzman et al. 1995) and is involved in regulating TNF-α expression in
macrophages in response to LPS. However, effects of LPS on Na/K-ATPase activity in
the heart are not known and no published study to date has examined the effect of Na/KATPase in regulating myocardial TNF-α protein production during endotoxemia.
Therefore, the second specific hypothesis of this thesis (Chapter 3) was that Rac1
promotes LPS-induced TNF-α production via inhibition of Na/K-ATPase (Figure 1.5).
Although ERK1/2, p38 and JNK1/2 are activated in cardiomyocytes during
endotoxemia, they show different effects on TNF-α expression (Peng et al. 2005b; Peng
et al. 2003b; Peng et al. 2009; Rosengart et al. 2000a; Thakur et al. 2006). Activated
ERK1/2 and p38 promote TNF-α expression (Peng et al. 2005b; Peng et al. 2003b;
Rosengart et al. 2000a; Thakur et al. 2006). In contrast, JNK1 decreases TNF-α
expression and improves cardiac function during endotoxemia through inactivating
ERK1/2 and p38 (Peng et al. 2009). However, the molecular mechanisms of the crosstalk among JNK, ERK1/2 and p38 are not fully understood. MKP-1 is an important
negative feedback regulator of innate immune response via its prolonging of p38 and
JNK activation and decreasing of the production of pro-inflammatory cytokines (Hammer
et al. 2006; Salojin et al. 2006; Zhao et al. 2006). To our knowledge, the effects of MKP-
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1 on myocardial TNF-α expression and myocardial dysfunction during endotoxemia have
not been investigated. It has been shown that Rac/MAPK is one of the pathways that
promote MKP-1 expression (Li et al. 1999). PAK1 is a downstream effector of Rac1 and
participates in modulating cardiomyocyte contractility and cardiac hypertrophy (Sheehan
et al. 2007; Sussman et al. 2000). There is evidence that PAK regulates proIL-1
expression in macrophages through activation of MAPKs (Hsu et al. 2001). Thus, the
third specific hypothesis of this thesis (Chapter 4) was that Rac1/PAK1 induces
myocardial MKP-1 expression via JNK1 in response to LPS. It was further hypothesized
that increased MKP-1 production limits TNF-α expression and improves heart function
in endotoxemia (Figure 1.5).
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Chapter 2: PI3K-mediated Rac1 promotes LPS-induced TNF-α expression and
cardiac dysfunction via NADPH oxidase
A version of this chapter has been published:
Zhang T, Lu X, Beier F, Feng Q. 2011. Rac1 activation induces tumor necrosis
factoralpha expression and cardiac dysfunction in endotoxemia. J Cell Mol Med 15:110921, Used with permission.

2.1 Introduction
Sepsis is a major consequence of infectious diseases and one of the leading causes
of death in the intensive care unit (Angus & Wax 2001). Myocardial dysfunction induced
by endotoxins or lipopolysaccharides (LPS) of Gram-negative bacteria is a common
complication of septic shock and renders septic patients at high risk of developing multiorgan failure, which is associated with high mortality (Court et al. 2002). The inhibitory
effect of LPS on cardiac function is mediated through the production of pro-inflammatory
cytokines (Parrillo et al. 1985). TNF-α is a major cytokine responsible for cardiac
dysfunction during sepsis (Bozkurt et al. 1998; Grandel et al. 2000; Meng et al. 1998;
Natanson et al. 1989; Oral et al. 1997; Peng et al. 2003; Tracey et al. 1986). However, the
molecular mechanisms underlying myocardial TNF-α production during sepsis are not
fully understood.
Rac GTPases are a subfamily of Ras-homologous (Rho) GTPases and act as
molecular switches, cycling between active GTP-bound and inactive GDP-bound states
(Burridge & Wennerberg 2004; Hordijk 2006). The switch is activated when an upstream
signal activates a guanine nucleotide exchange factor (GEF) which then acts to facilitate
the release of GDP from the Rac GTPase and the subsequent binding of GTP. Rac
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activity is terminated by hydrolysis of GTP to GDP, a process which is accelerated by
GTPase-activating proteins (GAPs). Rac is an intracellular transducer of signaling and
can interact with specific effectors that regulate diverse cellular functions, such as
cytoskeletal remodeling, microtubule stability, gene transcription, and superoxide (O2-)
production (Burridge & Wennerberg 2004; Hordijk 2006).
There are four different Rac proteins: the ubiquitously expressed Rac1, the
hematopoietic cell-specific Rac2, Rac3 that is expressed in the brain, liver, lung and
pancreas and widespread RhoG (Haataja et al. 1997). Previous studies have shown that
LPS increases Rac1 activity in phagocytes, however the effect of Rac1 on TNF-α
expression in these cells remains controversial (Monick et al. 2003; Sanlioglu et al. 2001;
Thakur et al. 2006). Rac1 is the predominant Rac protein in cardiomyocytes (Pracyk et al.
1998; Satoh et al. 2006). Furthermore, Rac1 is activated during LPS stimulation and
contributes to myocardial TNF-α expression (Zhu et al. 2009). However, regulation of
Rac1 activation during LPS stimulation is not fully understood. Phosphoinositide-3
kinases (PI3K) are a family of evolutionary conserved signaling molecules that mediate
many cellular responses. The production of phosphatidylinositol (3,4,5)-triphosphate
(PtdIns(3,4,5)P3) from PI3K activates Rac via a PtdIns(3,4,5)P3-sensitive GEF. However,
Rac can also be activated by PI3K-independent mechanisms (Welch et al. 2003).
Whether Rac activation in cardiomyocytes during LPS stimulation is mediated by PI3K
remains to be determined.
NADPH oxidase is an enzyme system that catalyzes the NADPH-dependent
reduction of oxygen to O2- and consists of multi-subunits including Nox2 (gp91phox),
p22phox, p40phox, p47phox, p67phox and Rac. It has been shown that NADPH oxidase is a
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major source of O2- in cardiomyocytes under pathophysiological conditions and
activation of Rac is essential for NADPH oxidase activation (Moldovan et al. 2006). We
have demonstrated that Nox2-containing NADPH oxidase plays a pivotal role in LPSinduced cardiac TNF-α production (Peng et al. 2005). However, the role of Rac1 in
cardiac dysfunction during sepsis remains unknown.
In the present study, we hypothesized that Rac1 was necessary for LPS-induced
TNF-α expression and myocardial dysfunction via NADPH oxidase activation. To test
this hypothesis, a cardiac-specific Rac1-deficient mouse was generated. Our results
demonstrated that LPS-induced Rac1 activation in cardiomyocytes is PI3K-dependent.
Rac1 deficiency blocked cardiomyocyte TNF-α expression and decreased LPS-induced
O2- generation. Furthermore, cardiac-specific deficiency of Rac1 improved myocardial
function in endotoxemia.

2.2 Materials and methods
2.2.1 Animals and preparation of neonatal mouse cardiomyocytes
The investigation conforms with the Guide for the Care and Use of Laboratory
Animals published by the US National Institute of Health (NIH Publication #85-23,
revised 1996) and experimental protocols were approved by Animal Use Subcommittee
at the University of Western Ontario. C57BL/6 wild-type (WT) and Rac1 floxed (Rac1f/f)
mice (Glogauer et al. 2003) were purchased from the Jackson Laboratory (Bar Harbor,
Maine). In Rac1f/f mice, LoxP sites were inserted at both sides of exon 1 of the Rac1
gene. Cre transgenic mice (CreTG/+) with over-expression of Cre recombinase under the
control of α-myosin heavy-chain (MHC) promoter were provided by Dr. E. Dale Abel

57
(University of Utah, UT). This Cre recombinase can excise the region between the loxP
sites and is specifically expressed in cardiomyocytes since is it under the control of the αMHC promoter. The generation of cardiomyocyte-specific Rac1 knockout mice
(Rac1CKO) was achieved by breeding Rac1f/f mice with CreTG/+ mice as we have recently
described (Rui et al. 2005).
2.2.2 Isolation and culturing of neonatal mouse cardiomyocytes
The neonatal cardiomyocytes were prepared and cultured according to methods
we have previously described (Song et al. 2000). The neonatal cardiomyocyte cultures
were prepared from mice born within 24 hours. For each cell culture, 5-10 neonatal
mouse hearts were isolated, washed and minced in sodium bicarbonate, Ca2+ and Mg2+free Hanks balanced salt solution (D-Hanks, Sigma, Oakville, Ontario). Cardiomyocytes
were dispersed by 10 min of incubation with 22.5 µg/mL liberase 4 (Roche, Laval,
Quebec) in D-Hanks at 37 °C with gentle agitation. Cells were collected by
centrifugation at 200 g for 5 min and re-suspended in 10% FCS-containing M199
medium (Sigma). Noncardiomyocytes were removed through 1 hour of preplating after
which cardiomyocytes were plated in M199 medium containing 10% fetal bovine serum
(FBS) on culture plates precoated with 1% gelatin (Sigma). Neonatal cardiomyocytes
were cultured in a humidified incubator at 37°C, in the presence of 5% CO2. A
subconfluent spontaneously beating monolayer of cardiomyocytes was formed within 2
days. Cells were treated with LPS (1 µg/ml, Sigma), apocynin (400 µM, Sigma),
LY294002 (10 µM, Sigma) and U0126 (10 µM, Sigma) or infected with adenoviruses.
2.2.3 Adenoviral infection of neonatal cardiomyocytes
Cardiomyocytes were infected with adenoviruses carrying a dominant-negative
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form of Rac1 (Ad-Rac1N17, Vector Biolabs, Philadelphia, PA), Cre recombinase (AdCre, Vector Biolabs, Philadelphia, PA) or green fluorescence protein (Ad-GFP, a gift
from Dr. J. Lipp, Medical University of Vienna, Austria) as a control, at a multiplicity of
infection (MOI) of 10 plaque forming units/cell. Adenovirus-mediated gene transfer was
implemented as previously described (Peng et al. 2003). Briefly, cells were incubated for
4 hours in the present of minimal volume of M199 containing adenoviruses. Following
the incubation, full volume of 10% FBS M199 was applied. All experiments were
performed after 48 hours of adenoviral infection.
2.2.4 Rac1 activity assay
Rac1 activity was measured using the EZ-Detect Rac1 activation kit (Pierce,
USA) according to the manufacturer’s protocol. Briefly, cells or tissues were lysed.
Thirty micrograms of protein lysates were taken to detect total Rac1 protein. At the same
time, 1 mg of protein lysates were incubated with 20 µg of glutathione S-transferase
(GST)-human Pak1-p21 binding domain at 4° C for 1 hour. The beads were washed three
times to remove the unbound material and were then boiled in 2x SDS buffer for 5
minutes to elute Rac1-GTP. Rac1-GTP and total Rac1 protein levels were detected by
western blot analysis using an anti-Rac1 antibody included in the kit. Rac1 activity was
expressed as a ratio of Rac1-GTP to total Rac1 proteins.
2.2.5 PI3K activity assay
PI3K activity in cultured cardiomyocytes or myocardial tissue lysates was
determined using a competitive ELISA kit (Echelon Biosciences, Salt Lake City, UT)
according to the manufacture’s protocol with modifications (Bonnans et al. 2006).
Briefly, cell or tissue lysates (25 µg protein) were incubated with phosphatidylinositol
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(4,5)-bisphosphate [PI(4,5)P2] substrate (100 pmol) in 100 µL kinase reaction buffer. The
reaction products were incubated with a PI(3,4,5)P3 detector protein, and then added to
the PI(3,4,5)P3-coated microplate for competitive binding. A peroxidase-linked
secondary detection reagent and colorimetric detection at 450 nm was used to detect
PI(3,4,5)P3 detector protein binding to the plate.
2.2.6 Measurement of TNF-α mRNA
Total RNA was extracted from cardiomyocytes using the Trizol Reagent (GibcoBRL) as per manufacturer's instructions. TNF-α mRNA levels were determined by realtime reverse-transcriptase polymerase chain reaction (RT-PCR) as as previously
described (Peng et al. 2003). Total RNA (1 µg) was reverse transcribed using random
hexamers. 28S rRNA was used as an internal control. The primers were: TNF-α upstream
5′-CCG ATG GGT TGT ACC TTG TC-3′ and downstream 5′-GGG CTG GGT AGA
GAA TGG AT-3′. 28S rRNA upstream 5’-TTG AAA ATC CGG GGG AGA G-3’ and
downstream 5’-ACA TTG TTC CAA CAT GCC AG-3’. Samples were amplied for 34
cycles using MJ Research Opticon Real-time PCR machine. The levels of TNF-α were
compared to that of 28S rRNA, and the relative expression of these genes was obtained.
2.2.7 Measurement of TNF-α protein
TNF-α protein levels were measured using a mouse TNF-α ELISA kit
(eBioscience, USA), according to the manufacturer’s instructions. Briefly, ELISA plates
were coated with coating buffer containing capture antibody for overnight. The wells
were washed and blocked with assay diluent. Standards and samples were added to the
appropriate well and incubated overnight at 4°C. After wash, wells were incubated with
the detection antibody for 1 hour and then avidin-HRP for 30 min at room temperature.
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After thorough washing, each well was incubated with substrate solution for 15 min.
Reaction was stopped by 1 M H3PO4. Plate was read at 450 nm. The concentration of
TNF-α was calculated according to the standard curve. The measurements were
standardized with cell numbers or expressed as TNF-α levels to total proteins.
2.2.8 Western blot analysis
Thirty micrograms of protein lysates were subjected to separation on a 10% SDSPAGE gel, followed by electrotransfer to nitrocellulose membranes. Blots were probed
with specific antibodies against ERK1/2 (1:500) and phospho-ERK1/2 (1:500), p38
(1:500) and phospho-p38 (1:500; Cell Signaling Technology, Danvers, MA), followed by
incubation with horseradish peroxidase-conjugated secondary antibodies (1:3000, Santa
Cruz Biotechnology, CA) respectively. Signals were detected by the chemiluminescence
detection method and quantified by densitometry.
2.2.9 Lucigenin assay
NADPH-dependent superoxide (O2-) generation was measured in cell lysates by
lucigenin-enhanced chemiluminescence (40 µg of protein, 100 µM β-NADH, 5 µM
lucigenin, sigma). The chemiluminescence was detected by a mutilabel counter
(SpectraMax M5, Molecular Devices). Replicates were incubated in the presence of the
flavoprotein inhibitor (diphenyleneiodonium, DPI, 10 µM) to ensure O2- was generated
from NADPH oxidase, as previously described (Peng et al. 2005). The light signal was
monitored for 1.5 seconds and counts per second (CPS) were presented as NADPH
oxidase activity that was DPI inhibitable.
2.2.10 Isolated mouse heart preparations
Adult Rac1f/f and Rac1CKO (male, 3 months old) mice were treated with LPS
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(2mg/kg, i.p.) or saline. After 2 hours, mouse hearts were isolated and perfused in a
Langendorff-system with Kreb’s-Henseleit buffer at 3 ml/min constant flow. The
perfusion buffer was kept at 37 °C and consistently bubbled with a mixture of 95% O2
and 5% CO2. Myocardial function was assessed as previously described with
modifications (Peng et al. 2005). Briefly, a 6-0 silk suture was passed through the apex of
the left ventricle and threaded through a light-weight rigid coupling rod, which was
connected to a force-displacement transducer (FT03) to record tension and heart rate. The
heart work was calculated by multiplying the force (g) by the heart rate (bpm). Maximal
and minimal first derivatives of force (+dF/dtmax and -dF/dtmin) which represent the rate
of contraction and relaxation respectively, were analyzed by PowerLab Chart program
(AD Instruments).
2.2.11 Statistical analysis
Results are presented as mean ± SEM from at least three independent
experiments. Differences between two groups were analyzed by a standard Student t-test.
For multigroup comparisons, one or two-way ANOVA followed by Student-NewmanKeuls or Bonferroni post-test was performed. P < 0.05 was considered statistically
significant.

2.3 Results
2.3.1 Myocardial Rac1 activation by LPS
To examine the effect of LPS on Rac1 activity, neonatal cardiomyocytes isolated
from C57BL/6 mice were treated with LPS (1 µg/ml) for 5, 15, 30 and 60 minutes. As
shown in Figure 2.1A, Rac1 activity in these cells peaked at 15 minutes and declined to
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Figure 2.1. LPS activates Rac1 in neonatal cardiomyocytes and in the adult myocardium.
A. Cardiomyocytes were isolated from WT mice, cultured for 48 hours, and then treated
with vehicle or LPS (1 µg/ml) for 5, 15, 30 and 60 minutes. Rac1 activity was measured
using the EZ-Detect Rac1 activation kit. B. Adult male Rac1f/f mice were treated with
LPS (2 mg/kg, i.p.) for 30 minutes. Rac1 activity in the left ventricular myocardium was
measured as described above. Data are means ± SEM from 3 - 4 mice or independent
experiments. *P<0.05 vs. control.
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about control levels by 60 minutes after LPS stimulation. To verify these in vitro results,
Rac1f/f mice were treated with LPS (2 mg/kg, i.p.) or saline for 30 minutes and
myocardial Rac1 activity was measured. In response to LPS, myocardial Rac1 activity
was significantly increased (P<0.05, Figure 2.1B). These data show that LPS activates
Rac1 in cardiomyocytes in vitro and in the myocardium in vivo.
2.3.2 Rac1 activation and cardiomyocyte TNF-α expression during LPS stimulation
To elucidate the role of Rac1 in LPS-induced TNF-α expression, neonatal
cardiomyocytes isolated from WT mice were infected with an adenovirus carrying a
dominant negative form of the Rac1 gene (Ad-Rac1N17), which selectively inhibits Rac1
activity. As shown in Figure 2.2A and 2.2B, overexpression of Rac1N17 significantly
decreased LPS-induced TNF-α mRNA and protein levels by 60% and 56%, respectively
(P<0.01). This result was further confirmed using Rac1 deficient cardiomyocytes.
Cultured neonatal cardiomyocytes from Rac1f/f mice were infected with Ad-Cre.
Expression of Cre recombinase in Rac1f/f cells decreased Rac1 protein levels by 70%
(Figure 2.2C). LPS-induced TNF-α mRNA and protein expression were reduced by 67%
and 41% in Ad-Cre infected Rac1f/f cells, respectively (P<0.05, Figure 2.2D and 2.2E).
These data showed that LPS-induced TNF-α expression requires Rac1 activity.
2.3.3 Involvement of PI3K in Rac1 activation in cardiomyocytes during LPS
stimulation
To investigate the involvement of PI3K in Rac1 activation in cardiomyocytes
during LPS stimulation, PI3K activity was determined. In response to LPS (1 µg/ml),
PI3K activity was significantly increased in cultured neonatal cardiomyocytes (P<0.05,
Figure 2.3A). In vivo treatment of LPS (2 mg/kg, i.p.) also activated PI3K in the
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Figure 2.2. Rac1 promotes LPS-induced TNF-α expression in neonatal cardiomyocytes.
WT cardiomyocytes were infected with Ad-GFP or Ad-Rac1N17 for 24 hours.
Cardiomyocytes were treated with LPS (1 µg/ml) for 3 hours or 5 hours. TNF-α mRNA
(A) and TNF-α protein in culture medium (B) were measured by real-time RT-PCR and
ELISA, respectively. Neonatal cardiomyocytes from Rac1f/f mice were infected with AdGFP and Ad-Cre for 24 hours. Rac1 protein was measured by Western blot analysis (C).
Rac1f/f cells, infected with Ad-GFP or Ad-Cre, were treated with LPS for 3 hours or 5
hours. TNF-α mRNA (D) and TNF-α protein in culture medium (E) were measured as
described above. Data are means ± SEM from 3 - 7 independent experiments. **P<0.01
vs. Ad-GFP; †P<0.05, †† P <0.01 vs. Ad-GFP+LPS.
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Figure 2.3. PI3K promotes LPS-induced Rac1 activation and TNF-α expression in
neonatal cardiomyocytes. Cultured WT neonatal cardiomyocytes was stimulated with
LPS at 1 µg/ml for 30 min. WT mice were treated with LPS (2 mg/kg, i.p.) for 30 min.
PI3K activities in cardiomyocytes (A) and myocardium (B) were determined by
competitive ELISA. Rac1 activities in WT cardiomyocytes (C) and myocardium (D)
stimulated with LPS for 30 minutes in the presence or absence of the PI3K inhibitor
LY294002 (LY, 10 µM and 7.5 mg/kg, i.p.) were determined by EZ-Detect Rac1
activation kit. WT cardiomyocytes were treated with LPS (1 µg/ml) in the presence or
absence of the PI3K inhibitor LY294002 for 3 or 5 hours. TNF-α mRNA (E) and TNF-α
protein in culture medium (F) were measured by real-time RT-PCR and ELISA,
respectively. Data are means ± SEM from 3 - 5 independent experiments. *P<0.05,
**P<0.01 vs. control or sham; †P<0.05, ††P<0.01 vs. LPS.
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myocardium in the adult mice (P<0.05, Figure 2.3B). To further study the contribution of
PI3K in LPS-induced Rac1 activation, cardiomyocytes were treated with LY294002, a
selective inhibitor of PI3K. Our data showed that LY294002 decreased LPS-induced
Rac1-GTP by 41% in cardiomyocytes (Figure 2.3C). Similarly, LPS-stimulated Rac1GTP levels in the myocardium were also blocked by 71% after LY294002 treatment
(Figure 2.3D). In addition, LY294002 significantly decreased LPS-induced TNF-α
mRNA and protein levels (P<0.05, Figure 2.3E and 2.3F). These results indicate that
Rac1 activation in cardiomyocytes is mediated by PI3K during LPS stimulation.
2.3.4 Role of PI3K and Rac1 in NADPH oxidase activation during LPS stimulation
Our lab has recently demonstrated that Nox2-containing NADPH oxidase
contributes to LPS-induced TNF-α expression in cardiomyocytes (Peng et al. 2005).
Consistent with this notion, the present study demonstrated that LPS increased NADPH
oxidase-mediated O2- generation (P<0.05, Figure 2.4A), which was blocked by apocynin,
a selective NADPH oxidase inhibitor. Moreover, apocynin, significantly reduced TNF-α
mRNA levels by 46% and protein levels by 43% in response to LPS (P<0.01, Figure
2.4D and 2.4E). To detect if PI3K activation mediates LPS-induced NADPH oxidase
activity, cardiomyocytes were treated with LY294002. Figure 2.4A showed that O2production stimulated by LPS was significantly blocked by LY294002. To determine
whether Rac1 is involved in regulating NADPH oxidase activity, cardiomyocytes were
treated with Ad-Rac1N17 to specifically block Rac1 activation. Our data showed that
LPS-induced O2- generation in these cells was significantly inhibited by Ad-Rac1N17
(P<0.05, Figure 2.4B). Similarly, O2- production was also significantly reduced in Rac1
deficient cardiomyocytes (P<0.05, Figure 2.4C). These results suggest that PI3K and
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Figure 2.4. PI3K and Rac1 promote LPS-induced superoxide (O2-) generation and TNFα expression in neonatal cardiomyocytes. A. Effects of apocynin and LY294002 on O2production. WT cells were treated with LPS (1 µg/ml) for 2 hours with or without
apocynin (400 µM) and LY294002 (LY, 10 µM). O2- production was measured by the
lucigenin assay. B. Effects of Ad-Rac1N17 on O2- production. WT cells were infected
with Ad–GFP or Ad-Rac1N17. O2- production was measured 2 hours after LPS treatment
(1 µg/ml). C. O2- production in Rac1 deficient cardiomyocytes. Rac1f/f cardiomyocytes
were infected with Ad-GFP or Ad-Cre for 24 hours followed by treatment with LPS for 2
hours. O2- production was measured. WT cardiomyocytes were treated with LPS (1
µg/ml) in the presence or absence of 400 µM apocynin for 3 and 5 hours. TNF-α mRNA
(D) and TNF-α protein in culture medium (E) were measured by real-time PCR analysis
and ELISA, respectively. Data are means ± SEM from 3 - 5 independent experiments.
*P<0.05, **P <0.01 vs. control and Ad-GFP; †P<0.05, ††P <0.01 vs. LPS and AdGFP+LPS.
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Rac1 are critical for NADPH oxidase activation in cardiomyocytes during LPS
stimulation.
2.3.5 Role of PI3K and Rac1 in ERK1/2 activation during LPS stimulation
We have previously shown that activation of ERK1/2 was essential for NADPH
oxidase signaling and LPS-induced TNF-α expression in cardiomyocytes (Peng et al.
2005). The effects of LPS on ERK1/2 activation were also determined in the present
study. As shown in Figure 2.5A, LPS rapidly increased phosphorylation of ERK1/2
which peaked at 30 minutes and returned to control levels after 2 hours. LPS-induced
ERK1/2 phosphorylation was completely blocked by a PI3K inhibitor, LY294002 (Figure
2.5B), suggesting that LPS regulated ERK1/2 activity via PI3K. To examine whether
Rac1 activity leads to ERK1/2 phosphorylation, ERK1/2 activation was measured in AdRac1N17 infected cardiomyocytes. Overexpression of Rac1N17 significantly decreased
LPS-induced phosphorylation of ERK1/2 compared with Ad-GFP infected group (Figure
2.5C). Furthermore, U0126, a selective ERK1/2 inhibitor, decreased LPS-stimulated
TNF-α mRNA and protein levels by 46% and 69%, respectively (Figure 2.5D and 2.5E).
Taken together, these results suggest that the effects of PI3K and Rac1 on
cardiomyocytes are mediated by ERK1/2.
2.3.6 Role of Rac1 in myocardial dysfunction during endotoxemia
To study the role of Rac1 in myocardial depression during endotoxemia in vivo,
we generated cardiac-specific Rac1 knockout mice (Rac1CKO) using Cre-loxP
recombination as described in the methods. Our data showed that the Rac1 protein was
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Figure 2.5. PI3K and Rac1 promote LPS-induced ERK1/2 phosphorylation in neonatal
cardiomyocytes. A. WT cardiomyocytes were treated with vehicle or LPS (1 µg/ml) for
15 min, 30 min, 1 hour and 2 hours. ERK1/2 phosphorylation in these cells was measured
by Western blot analysis. B. WT cardiomyocytes were treated with LPS (1 µg/ml) for 30
min with or without LY294002 (LY, 10 µM). ERK1/2 phosphorylation in these cells was
measured. C. Neonatal cardiomyocytes were infected with Ad-GFP or Ad-Rac1N17 for
24 hours. Cardiomyocytes were treated with LPS (1 µg/ml) for 30 min. ERK1/2
phosphorylation was measured as described above. D and E. Cardiomyocytes were
treated with LPS with or without the ERK1/2 inhibitor U0126 (10 µM) for 3 and 5 hours.
TNF-α mRNA (D) and protein in culture medium (E) were measured by real-time RTPCR and ELISA, respectively. Data are means ± SEM from 3-5 independent
experiments. *P<0.05, **P<0.01 vs. control; †P<0.05, ††P<0.01 vs. Ad-GFP+LPS and
LPS.
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Figure 2.6. TNF-α expression in Rac1f/f and Rac1CKO adult mouse myocardium during
endotoxemia. A. Rac1 protein expression in heart, skeletal muscle and lungs in Rac1f/f
and Rac1CKO mice as determined by Western blot analysis. TNF-α mRNA (B) and
protein (C) levels in Rac1f/f and Rac1CKO heart tissues were measured after 2 and 4 hours
of LPS treatment (2 mg/kg, i.p.). Data are means ± SEM, n=3 to 10 per group. ** P<0.01
vs. sham Rac1f/f, † P <0.05 vs. LPS Rac1f/f.
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Figure 2.7. Cardiac function in Rac1f/f and Rac1CKO mice after 2 hours of LPS treatment
(2 mg/kg, i.p.). Mouse hearts were isolated and perfused using the Langendorff system.
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selectively knocked-down in the heart but not in the skeletal muscle and lungs in
Rac1CKO mice (Figure 2.6A). Rac1CKO and Rac1f/f mice were treated with vehicle or LPS
(2 mg/kg, i.p.). Our data demonstrated that LPS-induced myocardial TNF-α mRNA and
protein levels were significantly decreased (P<0.01, Figure 2.6B and 6C). After 2 hours
of LPS in vivo treatment, cardiac function was determined using the Langendorff
preparation. The rate of contraction and relaxation, heart rate, and heart work were
significantly reduced in both Rac1f/f and Rac1CKO mice after endotoxemia (P<0.05,
Figure 2.7). However, compared with Rac1f/f mice, heart work and rate of contraction
(+dF/dtmax) were significantly increased in Rac1CKO mice (P<0.05, Figure 2.7).

2.4 Discussion
The present study demonstrated for the first time that Rac1-mediated TNF-α
expression following LPS stimulation occurs downstream of PI3K signaling in
cardiomyocytes. Rac1 activation increased O2- generation, and ERK1/2 MAPK
phosphorylation leading to increased TNF-α expression in cardiomyocytes. More
importantly, our study provided evidence that cardiac-specific Rac1 deficiency improved
cardiac function during endotoxemia. PI3K-mediated activation of Rac1 represents a
novel signaling pathway by which LPS induces cardiomyocyte TNF-α expression and
cardiac dysfunction (Figure 2.8).
Rho GTPases are a large family of proteins that include the Rac proteins (Rac1, 2
and 3) as well as RhoA and Cdc42. The role of Rho GTPases on TNF-α production
during LPS stimulation has been studied, but the results differ depending on cell types

74

LPS
TLR4
Nox2
a
lemm
o
c
r
a
S

Rac1
GTP

PI3K

p47phox
p67phox

p40phox

NADPH oxidase

PtdIns(3,4,5)P3
Rac1
GDP

p22phox

Rac1
GTP
O2
ERK1/2
TNF-!

Cardiac Dysfunction

Figure 2.8. Schematic of Rac1 signaling pathway leading to cardiomyocyte TNF-α
expression and cardiac dysfunction during LPS stimulation. LPS activates Rac1 via
PI3K/PtdIns(3,4,5)P3 signaling. Activation of Rac1 activates NADPH oxidase leading to
production of O2-, phosphorylation of ERK1/2 MAPK, and expression of TNF-α.
Increased myocardial TNF-α production results in cardiac dysfunction during
endotoxemia. TLR4, toll-like receptor 4.
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and experimental conditions (Fessler et al. 2007; Monick et al. 2003; Sanlioglu et al.
2001; Thakur et al. 2006). For example, toxin B, an inhibitor Rho GTPase family,
increased TNF-α production in macrophages in both basal and endotoxemic conditions
(Monick et al. 2003). In resting neutrophils, RhoA suppresses TNF-α production by
inhibiting NF-κB activity (Fessler et al. 2007). Upon LPS stimulation, RhoA is activated
and increases TNF-α expression, suggesting a dual role of RhoA in TNF-α production in
human neutrophils (Fessler et al. 2007). Additionally, studies have shown that Rac1
activation promoted LPS-induced TNF-α expression in macrophages and Kupffer cells
(Sanlioglu et al. 2001; Thakur et al. 2006). Furthermore, Rac1 mediates myocardial TNFα expression during LPS stimulation (Zhu et al. 2009). However, the role of Rac1 in
cardiac dysfunction during endotoxemia remains unknown. In the present study, we
demonstrated that Rac1 is rapidly and transiently activated by LPS in cultured neonatal
cardiomyocytes and in the adult myocardium. Rac1 inhibition or deficiency blocked LPSinduced TNF-α production. Furthermore, Rac1CKO mice showed significant improvement
in cardiac function during endotoxemia, which was assessed using the Langendorff
preparation to avoid the influence of other organs, the systemic circulation and signals
from both the central and the autonomic nervous systems. Thus, both in vitro and in vivo
evidence from our study demonstrate that LPS activates Rac1 and promotes
cardiomyocyte TNF-α expression leading to cardiac dysfunction.
Rac GTPases are regulated by GEFs that promote the exchange of GDP for GTP,
and GAPs that accelerate the hydrolysis of GTP. Available evidence suggests that Rac
activation depends mainly on the activation of GEFs (Welch et al. 2003). In this regard,
Rac-activating GEFs such as Vav, Sos, PIX, SWAP-70 and P-Rex, can be activated by
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phosphoinositol-3-kinase (PI3K) (Welch et al. 2003). The PI3K family is divided into
three major classes: type 1, type II and type III. The type I PI3K comprises a catalytic
subunit, p110 and a regulatory adapter subunit p85. Activated type I PI3K is recruited to
the plasma membrane, where it can phosphorylate its main substrate PtdIns(4,5)P2 and
thereby generate PtdIns(3,4,5)P3. The type II PI3K uses phosphatidylinositol (PI) and
PtdIns(4)P as substrates and forms PtdIns(3)P and PtdIns(3,4)P2, respectively. The type
III PI3K phosphorylates phoshatidylinositol (PtdIns) to produce phosphoinositol-3-P
(PtdIns(3)P). PtdIns(3,4,5)P3, the production of the type I PI3K, can interact with the
homology (PH) domain of target proteins, including GEFs, and promote protein
activation (Welch et al. 2003). In the present study, type I PI3K activity, as determined
by PtdIns(3,4,5)P3 levels, was significantly increased in cultured cardiomyocytes in vitro
and in the myocardium in vivo during LPS stimulation. Inhibition of PI3K activity by a
selective inhibitor, LY294006, significantly decreased Rac1-GTP levels and resulted in a
concomitant decrease in TNF-α expression stimulated by LPS. These results indicate that
PI3K is required for Rac1 activation in cardiomyocytes during LPS stimulation.
Activated Rac1 interacts with specific effectors that regulate diverse physiological
functions. One of these effectors is p67phox, a subunit of NADPH oxidase (Bosco et al.
2009). A critical step for NADPH oxidase assembly and activation is the heterodimerization of Nox2 with p67phox (Dang et al. 2001). Interestingly, the interaction
between p67phox and Rac1 results in increased affinity of p67phox for Nox2 (Nisimoto et
al. 1997). In addition, recent studies involving p67phox–Rac1 chimeras have reported that
Rac1 induced an "activating" conformational change in p67phox (Gorzalczany et al. 2002;
Sarfstein et al. 2004). Thus, Rac proteins are required for NADPH oxidase activation and
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superoxide production. NADPH oxidase is an important source of reactive oxygen
species in the heart and activation of NADPH oxidase has been shown to contribute to
the pathogenesis of cardiovascular diseases including: cardiac hypertrophy (Bendall et al.
2002), hypertension (Rajagopalan et al. 1996), atherosclerosis (Warnholtz et al. 1999)
and heart failure post myocardial infarction (Gao et al. 2008; Murdoch et al. 2006). We
have recently demonstrated that NADPH oxidase is activated in cardiomyocytes which
results in myocardial TNF-α expression and cardiac dysfunction during endotoxemia
(Peng et al. 2005). In agreement with these data, the present study demonstrated that LPS
increases O2- generation. Inhibition of NADPH oxidase activity by apocynin significantly
decreased LPS-induced TNF-α expression in cardiomyocytes by 50%. This partially
inhibitory effect of apocynin on TNF-α expression also indicates the exitance of other
parallel signaling pathways, such as eNOS and PLCγ pathways, accounting for the
remaining TNF-α expression (Zhang & Feng 2010). Furthermore, we showed that
inhibition of PI3K activity decreased LPS-induced O2- production. Similarly, deficiency
in Rac1 or overexpression of dominant-negative Rac1 significantly suppressed O2generation and TNF-α expression in response to LPS stimulation. These results suggest
that PI3K-mediated Rac1 activity promotes neonatal cardiomyocyte TNF-α expression
induced by LPS via activation of NADPH oxidase.
MAPKs (p38, ERK1/2 and JNKs) are key signaling molecules involved in the
regulation of many biological processes including inflammatory responses and the
expression of pro-inflammatory cytokines. Indeed, activation of ERK1/2 and p38
regulates the expression of TNF-α in phagocytes during sepsis (Fessler et al. 2007;
Rosengart et al. 2000; Thakur et al. 2006). We have recently demonstrated that ERK1/2
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is downstream of NADPH oxidase signaling in LPS-induced TNF-α expression (Peng et
al. 2005). In the present study, we showed that LPS increased the phosphorylation of
ERK1/2 in cultured neonatal cardiomyocytes. Inhibition of PI3K and Rac1 activity
blocked LPS-stimulated ERK1/2 phosphorylation. Moreover, inhibition of ERK1/2
activity decreased LPS-induced TNF-α production. Thus, PI3K-mediated Rac1 activity
regulates LPS-induced TNF-α expression in cardiomyocytes via ERK1/2 activation.
In summary, the present study provides strong evidence that Rac1 activation is
required for cardiomyocyte TNF-α expression and cardiac dysfunction during
endotoxemia. Activation of Rac1 through PI3K increases NADPH oxidase and ERK1/2
activity, leading to increased myocardial TNF-α expression during LPS stimulation
(Figure 2.8). Our study suggests that Rac1 may represent a novel therapeutic target for
TNF-α expression and myocardial dysfunction in sepsis.
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Chapter 3. Rac1 promotes LPS-induced TNF-α production via Na/K-ATPase
3.1 Introduction
Sepsis is a leading cause of death in hospital intensive care units. Myocardial
expression of pro-inflammatory cytokines, especially tumor necrosis factor-alpha (TNFα) contributes to cardiac dysfunction and high mortality (40-80%) (Dellinger et al. 2008;
Merx & Weber 2007; Parrillo et al. 1985). However the underlying molecular
mechanisms of cardiac TNF-α production during sepsis remain elusive.
Na/K-ATPase catalyzes ATP hydrolysis to actively transport 3 Na+ ions out of
and 2 K+ into the cell, and thus maintains trans-membrane gradients of Na+ and K+.
Changes in intracellular Na+ regulate intracellular Ca2+ via the Na+/Ca2+ exchanger (Bers
et al. 2006). In cardiomyocytes, Na/K-ATPase activity is inhibited by phospholemman
(Han et al. 2006) and glutathionylation induced by NADPH oxidase (Figtree et al. 2009).
In addition, Na/K-ATPase also acts as a signal transducer that regulates protein kinases
including Src and ERK (Li & Xie 2009). In the heart, Na/K-ATPase modulates
cardiomyocyte apoptosis (Sapia et al. 2010), contractility (Barwe et al. 2009; James et al.
1999) and hypertrophy (Huang et al. 1997) via Ca2+-dependent mechanisms. LPS inhibits
Na/K-ATPase activity in the lung (Koksel et al. 2006) and kidney (Guzman et al. 1995).
Inhibition of Na/K-ATPase potentiates LPS-induced-cytokine expression including TNFα in macrophages (Ohmori et al. 1991). Although we have previously shown that LPS
increases intracellular Ca2+ in cardiomyocytes (Geoghegan-Morphet et al. 2007), changes
in Na/K-ATPase activity were not studied. Thus, the role of Na/K-ATPase in myocardial
TNF-α expression during endotoxemia remains unknown.
Mammalian target of rapamycin (mTOR), a Ser/Thr protein kinase, acts as a
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central regulator of cell growth and metabolism by controlling protein synthesis and other
cellular processes (Hay & Sonenberg 2004). It is sensitive to tuberous sclerosis complex
(TSC)1/TSC2 activation and intracellular Ca2+ concentration (Hay & Sonenberg 2004;
Hoyer-Hansen et al. 2007; Lenz & Avruch 2005). Studies have shown that mTOR
contributes to cardiac hypertrophy (McMullen et al. 2004; Shioi et al. 2003) and
ventricular remodeling after myocardial infarction (Buss et al. 2009). LPS activates
mTOR (Baker et al. 2009; Chen et al. 2010; Haidinger et al. 2010; Weichhart et al. 2008),
however its role in pro-inflammatory cytokine expression during sepsis remains
controversial. For example, mTOR activation by LPS promotes TNF-α and interleukin12 expression in monocyte-derived dendritic cells (Haidinger et al. 2010). On the
contrary, mTOR activation inhibits TNF-α production in monocytes (Weichhart et al.
2008), macrophages (Baker et al. 2009) and HL-1 cells during LPS stimulation (Song et
al. 2010). Thus, the effects of mTOR activation are cell type specific. Importantly, the
role of mTOR in myocardial TNF-α protein production during endotoxemia remains
unknown.
In the present study, we hypothesized that myocardial Na/K-ATPase activity is
inhibited during endotoxemia via PI3K/Rac1/NADPH oxidase pathway. We further
hypothesized that inhibition of Na/K-ATPase activates Ca2+/CaMK-dependent mTOR,
leading to enhanced TNF-α protein production in cardiomyocytes during LPS
stimulation. To test these hypotheses, cultured cardiomyocytes and in vivo endotoxemia
mouse models were employed. Our study demonstrated a novel function of Na/K-ATPase
in the regulation of myocardial TNF-α expression during endotoxemia.
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3.2. Materials and Methods
3.2.1 Animals and preparation of neonatal mouse cardiomyocytes
The investigation conforms with the Guide for the Care and Use of Laboratory
Animals published by the US National Institute of Health (NIH Publication #85-23,
revised 1996) and experimental protocols were approved by Animal Use Subcommittee
at the University of Western Ontario. C57BL/6 wild-type (WT) and Rac1 floxed (Rac1f/f)
mice (Glogauer et al. 2003) were purchased from the Jackson Laboratory (Bar Harbor,
Maine). Cre transgenic mice (CreTG/+) which overexpress Cre recombinase under the
control of a-myosin heavy-chain (MHC) promoter were provided by Dr. E. Dale Abel
(University of Utah, UT). The generation of cardiomyocyte-specific Rac1 knockout mice
(Rac1CKO) was achieved by breeding Rac1f/f mice with CreTG/+ mice (Rui et al. 2005).
3.2.2 Isolation and culturing of neonatal mouse cardiomyocytes
The neonatal cardiomyocytes were prepared and cultured according to methods
we have previously described (Song et al. 2000; Chapter 2). Cells were treated with LPS
(Sigma, Oakville, Ontario, Canada), apocynin (Sigma), ouabain (Sigma), KN-93 (Sigma),
rapamycin (Cell Signaling Technology, Danvers, MA) or infected with adenoviruses.
3.2.3 Adenoviral infection of neonatal cardiomyocytes
Cardiomyocytes were infected with adenoviruses carrying a dominant-negative
form of Rac1 (Ad-Rac1N17, Vector Biolabs, Philadelphia, PA), green fluorescence
protein (Ad-GFP, a gift from Dr. J. Lipp, Medical University of Vienna, Austria) and
LacZ (Ad-LacZ, Vector Biolabs, Philadelphia, PA) at a multiplicity of infection (MOI) of
10 plaque forming units/cell. Adenovirus-mediated gene transfer was applied as
previously described (Peng et al. 2003; Chapter 2).
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3.2.4 Na/K-ATPase activity assay
Na/K-ATPase activity in neonatal cardiomyocytes and LV myocardium was
determined by a fluorometric method with modifications (Barr et al. 2005; Johansson et
al. 2003). Briefly, homogenates were prepared in a buffer containing 250 mM sucrose, 2
mM EDTA, 1.25 mM EGTA, 5 mM NaN3, and 10 mM Tris (pH 7.4). Homogenates were
freeze-thawed four times. 30 µg protein lysates were incubated for 5 min at 37°C in a
buffer containing 5 mM MgCl2, 1.25 mM EDTA, 100 mM Tris base (pH 7.4), 1 mM
EGTA, and 5 mM NaN3, with or without 6 mM ouabain. 3-O-methylfluorescein
phosphate (3-O-MFP, 160 µM) was added to the lysates followed by incubation at 37°C
for 1 min. Activated Na/K-ATPase hydrolyzes 3-O-MFP and forms a fluorescent
compound 3-O-MF. To activate Na/K-ATPase, 10 mM KCl was added and fluorescence
was recorded. The excitation and emission wavelengths were 470 nm and 515 nm,
respectively. The amplitude of the emission was shown to be proportional to the
concentration of 3-O-MF, and a standard curve was created using varying concentration
of 3-O-MF. K+-dependent 3-O-MFPase activity was determined by subtracting activity
with KCl from the activity without KCl. Na/K-ATPase activity was determined by
subtracting K+-dependent 3-O-MFPase activity without ouabain from the activity with
ouabain and expressed as micromoles of liberated phosphate (Pi) per minute per
milligram protein.
3.2.5 Measurement of TNF-α mRNA
Total RNA was extracted from cardiomyocytes using the Trizol Reagent (GibcoBRL) as per manufacturer's instructions. TNF-α mRNA levels were determined by realtime reverse-transcriptase polymerase chain reaction (RT-PCR) as as previously
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described (Peng et al. 2003; Chapter 2). TNF-α mRNA stability was assessed in the
present of a transcription inhibitor, actinomycin D. Neonatal cardiomyocytes were
stimulated with LPS (0.1 µg/ml) with or without ouabain (50 µM) for 3 hours followed
by actinomycin D (5 µg/ml) treatment. After 20, 60 and 120 minutes of actinomycin D
exposure, total RNA was extracted from cardiomyocytes. TNF-α mRNA levels were
measured.
3.2.6 Measurement of TNF-α protein
TNF-α protein levels were measured using a mouse TNF-α ELISA kit
(eBioscience, USA), according to the manufacturer’s instructions. The measurements
were standardized with cell numbers or expressed as TNF-α levels to total proteins.
3.2.7 [3H]-Leucine incorporation
Neonatal cardiomyocytes were seeded into 12-well plates (8×105 cells/well). After
48 hours, cells were treated with LPS (1 µg/ml) with or without rapamycin (10 nM) in the
present of [3H]-leucine (1 µCi/ml, Amersham, GE Healthcare, Baie d’Urfe, Quebec) for 5
hours. Cells were then washed 3 times with ice-cold PBS. Proteins were precipitated with
5% tricholoroacetic acid (TCA) for 30 minutes on ice. Cell precipitates were washed 2
additional times with TCA and solubilized in 0.2 M NaOH. The radioactivity of [3H]leucine incorporated into proteins were measured by a liquid scintillation counter (TriCarb 2900TR, Perkin-Elmer, Woodbridge, Ontario).
3.2.8 Adult cardiomyocyte isolation
Cardiomyocytes were isolated from the hearts of adult male Rac1f/f and Rac1CKO
mice as previously described with modifications (Burger et al. 2009). Hearts were
mounted on a Langendorff system and perfused with digestion buffer containing 75
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µg/mL of liberase blendzyme IV (Roche, Laval, Quebec). Following digestion, cells were
resuspended and exposed to a series of sedimentation and resuspension steps in buffer
containing increasing concentrations of Ca2+ (12.5 µM-1.5 mM). Healthy, rod-shaped
myocytes were used for measurements of Ca2+ transients.
3.2.9 Intracellular Ca2+ transients
Free intracellular Ca2+ concentrations ([Ca2+]i) were measured in isolated
ventricular cardiomyocytes using fura-2-AM as previously described (Burger et al. 2009).
Cells were loaded with 1 µM fura-2-AM and then paced at 0.5, 1, 2 and 4 Hz using a 2.5
ms duration pulse. Fluorescence intensity at 510 nm was measured with alternating 345
and 380 nm excitation using a Deltascan monochrometer system (Photon Technology
International, London, ON, Canada). [Ca2+]i was calculated by the methods of
Grynkiewicz (Grynkiewicz et al. 1985).
3.2.10 Western blot analysis
Thirty micrograms of protein lysates were subjected to separation on a 10% SDSPAGE gel, followed by electrotransfer to nitrocellulose membranes. Blots were probed
with specific antibodies against total mTOR (1:1000) and phospho-mTOR (1:1000; Cell
Signaling Technology, Danvers, MA), followed by incubation with horseradish
peroxidase-conjugated secondary antibodies (1:3000, Santa Cruz Biotechnology, CA)
respectively. Signals were detected by the chemiluminescence detection method and
quantified by densitometry. The relative phosphorylation levels of mTOR under various
experimental conditions were estimated by taking the ratio of the densitometric signal
acquired with anti-phospho-mTOR to the corresponding signal acquired with anti-mTOR.
3.2.11 Statistical analysis
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Results are presented as mean ± SEM. Differences between two groups were
analyzed by unpaired Student t-test. For multigroup comparisons, one or two-way
ANOVA followed by Student-Newman-Keuls or Bonferroni post-test was performed. A
P value less than 0.05 was considered statistically significant.

3.3 Results
3.3.1 LPS inhibits myocardial Na/K-ATPase activity
To examine the effect of LPS on Na/K-ATPase activity, neonatal cardiomyocytes
isolated from C57BL/6 mice were treated with LPS (1 µg/ml) for 2 hours. LPS decreased
Na/K-ATPase activity by 44% (Figure 3.1A). To study Na/K-ATPase activity in the
myocardium in vivo, Rac1f/f mice were treated with LPS (2 mg/kg, i.p.) or saline for 1, 2,
3 or 4 hours, after which hearts were obtained and myocardial Na/K-ATPase activity was
measured. After 2 hours of LPS treatment, myocardial Na/K-ATPase activity was
decreased by 93%, and returned back to control levels at 4 hours (Figure 3.1B). These
data showed that LPS strongly inhibits Na/K-ATPase activity in cardiomyocytes in vitro
and in myocardium in vivo.
3.3.2 Inhibition of Na/K-ATPase promotes TNF-α protein production during LPS
stimulation
TNF-α is a major pro-inflammatory cytokine contributing to cardiac dysfunction
during endotoxemia. To elucidate the role of Na/K-ATPase on LPS-induced TNF-α
expression, neonatal cardiomyocytes were incubated with ouabain, a selective inhibitor of
Na/K-ATPase. A concentration-dependent enhancement of LPS-induced TNF-α protein
levels was observed following ouabain treatment (Figure 3.2A). Surprisingly, ouabain
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Figure 3.1. LPS inhibits myocardial Na/K-ATPase activity. (A) Neonatal
cardiomyocytes from WT mice were treated with vehicle or LPS (1 µg/ml) for 2 hours.
Na/K-ATPase activity in these cells was determined using a fluorometric assay. (B)
f/f
Adult male Rac1 mice were treated with LPS (2 mg/kg, i.p. injection) for 1, 2, 3 and 4
hours. Na/K-ATPase activity in the left ventricular myocardium was determined. Data
are means ± SEM from 3-5 independent experiments. *P<0.05, **P<0.01 vs. control.
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Figure 3.2. Ouabain enhances LPS-induced TNF-α expression. Neonatal cardiomyocytes
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hours. (A) TNF-α protein levels in culture medium were measured by ELISA. (B) TNFα mRNA levels in cardiomyocytes were determined by real-time RT-PCR. (C) Stability
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had no measurable effect on LPS-induced TNF-α mRNA expression (Figure 3.2B).
Furthermore, ouabain did not alter TNF-α mRNA stability during LPS stimulation
(Figure 3.2C). These data indicate that inhibition of Na/K-ATPase activity enhances
LPS-induced TNF-α protein levels without any apparent effects on its mRNA expression
or stability in cardiomyocytes.
3.3.3 Inhibition of Na/K-ATPase by LPS is mediated by the PI3K/Rac1/NADPH
oxidase pathway
We have recently shown that the PI3K/Rac1/NADPH oxidase pathway is
activated and important for cardiac TNF-α production during endotoxemia (Zhang et al.
2011 Chapter 2; Zhu et al. 2009). To determine if PI3K acts as an up-stream regulator of
Na/K-ATPase, the PI3K inhibitor LY294002 was employed. LY294002 had no effect on
Na/K-ATPase activity under control conditions but completely restored Na/K-ATPase
activity after LPS stimulation in neonatal cardiomyocytes (Figure 3.3A). These results
were further confirmed in vivo. Adult male WT mice were pretreated with LY294002
(7.5 mg/kg, i.p.) for 30 minutes followed by LPS stimulation (2 mg/kg, i.p.). The dose of
LY294002 was chosen from our recent study, which showed significant inhibition of
PI3K-mediated responses in mice (Wu et al. 2011). As shown in Figure 3.3B, LY294002
blocked myocardial Na/K-ATPase activity suppression by LPS, indicating that LPS
inhibits cardiac Na/K-ATPase activity via PI3K.
To determine the effect of Rac1 on Na/K-ATPase activity, neonatal
cardiomyocytes isolated from WT mice were infected with an adenovirus encoding a
dominant negative form of Rac1 (Ad-Rac1N17), which specifically inhibits Rac1
activity. Overexpression of Rac1N17 restored Na/K-ATPase activity inhibited by LPS
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Figure 3.3. LPS-induced PI3K, Rac1 and NADPH oxidase activities suppress Na/KATPase. (A) WT neonatal cardiomyocytes were treated with LPS (1 µg/ml) with or
without LY294002 (LY, 10 µM) for 2 hours. Na/K-ATPase activity in these cells was
measured. (B) Adult male C57BL/6 mice were pretreated with saline (control) or
LY294002 (7.5 mg/kg) for 30 minutes followed by treatment with LPS (2 mg/kg, i.p.) for
2 hours. Na/K-ATPase activity in the LV myocardium was determined. (C) WT neonatal
cardiomyocytes were infected with Ad-LacZ or Ad-Rac1N17 for 24 hours followed by
treatment with LPS (1 µg/ml). Na/K-ATPase activity was measured. (D) Na/K-ATPase
f/f
CKO
activity in Rac1 and Rac1
myocardium were measured after 2 hours of LPS
treatment (2 mg/kg, i.p.). (E) Cells were incubated with LPS with or without apocynin
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(Figure 3.3C). Consistently, LPS decreased Na/K-ATPase activity in the myocardium of
Rac1f/f mice but had no effect on Rac1CKO mice (Figure 3.3D). To determine if NADPH
oxidase regulates Na/K-ATPase activity in response to LPS, neonatal cardiomyocytes
were treated with apocynin, a specific inhibitor of NADPH oxidase. Apocynin prevented
the diminution of Na/K-ATPase activity in response to LPS (Figure 3.3E). Taken
together, these data implicate the PI3K/Rac1/NADPH oxidase pathway in the inhibition
of myocardial Na/K-ATPase activity during LPS stimulation.
3.3.4 LPS-induced intracellular Ca2+ is mediated by Rac1
Inhibition of Na/K-ATPase is known to increase intracellular Ca2+ (Bers et al.
2006). Since LPS-induced inhibition of Na/K-ATPase is mediated by Rac1 as shown
above, the role of Rac1 in intracellular Ca2+ during LPS stimulation was studied. To this
end, Ca2+ transients were recorded using fura-2 in adult cardiomyocytes isolated from
Rac1f/f and Rac1CKO mice. These cells were paced over a range of frequencies (0.5 to 4
Hz) (Figure 3.4A-G). Rac1CKO cells showed lower systolic Ca2+ compared with Rac1f/f
cells, but diastolic Ca2+ was similar between these two groups (Figure 3.4A-C). In
addition, systolic and diastolic Ca2+, and the difference between systolic and diastolic
Ca2+ concentrations were all significantly increased by LPS stimulation in Rac1f/f
cardiomyocytes, but not in Rac1CKO cells (Figure 3.4A-C). Collectively, these data
suggest that Rac1 is not only required for maintaining cardiac Ca2+ homeostasis under
basal physiological conditions but also contributes to increased intracellular Ca2+ in
response to LPS.
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Figure 3.4 Rac1 increases LPS-induced intracellular Ca transient in cardiomyocytes.
f/f
CKO
Adult cardiomyocytes from Rac1 and Rac1
hearts treated with vehicle or LPS (5
2+
µg/ml) for 30 minutes were paced at 0.5, 1, 2 and 4 Hz. Intracellular Ca transients were
recorded. (A) Systolic, (B) diastolic and (C) difference between systolic and diastolic
2+
intracellular Ca concentrations in response to pacing were determined. (D) and (F)
f/f
CKO
representative tracings from Rac1 and Rac1 , respectively. (E) and (G) representative
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CKO
tracings from Rac1 and Rac1
stimulated by LPS respectively. Data are mean ± SEM
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from 4-6 mice per group (8-12 cells). *P<0.05 vs. Rac1 ; †P<0.05 vs. Rac1 +LPS.
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3.3.5 Ca2+/CaMK mediates LPS-induced TNF-α expression
Ca2+/calmodulin-dependent protein kinase (CaMK) activation promotes TNF-α
expression in monocytes and macrophages (Liu et al. 2008; Mendez-Samperio et al.
2006; Rosengart et al. 2000). To determine if CaMK regulates TNF-α expression in
cardiomyocytes, neonatal cardiomyocytes were pretreated with KN-93, a CaMK
inhibitor. KN-93 decreased LPS-induced TNF-α mRNA and protein levels in a dosedependent manner (Figure 3.5A and B).
3.3.6 mTOR mediates LPS-induced TNF-α protein expression
To gain insight into the molecular mechanisms by which Na/K-ATPase regulates
TNF-α protein production, we studied mTOR, a master regulator of protein synthesis,
activation during endotoxemia. Our data showed that mTOR phosphorylation was
significantly increased in neonatal cardiomyocytes in response to LPS stimulation (Figure
3.6A). Inhibition of mTOR by rapamycin resulted in a significant decrease in LPSinduced TNF-α protein levels in a dose-dependent manner without any effect on TNF-α
mRNA expression (Figure 3.6B and C).
To assess the effects of the above treatments on global protein synthesis, [3H]leucine incorporation was determined in cultured cardiomyocytes. In response to LPS,
[3H]-leucine incorporation showed a trend but not significant increase compared to
controls (Figure 3.6D). Importantly, treatment with rapamycin did not have a significant
effect on [3H]-leucine incorporation during LPS stimulation (Figure 3.6D). Taken
together, our data showed that inhibition of mTOR by rapamycin selectively decreases
LPS-induced TNF-α protein synthesis.
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Figure 3.5. Inhibition of CaMK activity diminishes LPS-induced TNF-α production. WT
neonatal cardiomyocytes were treated with vehicle or LPS (1 µg/ml) with or without KN93. TNF-α protein (A) and mRNA (B) levels were measured at 5 and 3 hours after LPS
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3.3.7 mTOR activation is mediated by Rac1/ Na/K-ATPase /CaMK signaling
To determine the role of Rac1/ Na/K-ATPase / CaMK signaling on mTOR
activity during LPS stimulation, neonatal cardiomyocytes were treated with AdRac1N17, ouabain and KN-93, respectively. Rac1N17 and KN-93 blocked LPS-induced
mTOR phosphorylation (Figure 3.7A and C). In contrast, ouabain enhanced mTOR
phosphorylation induced by LPS (Figure 3.7B). Taken together, these data suggest that
Rac1/ Na/K-ATPase/ CaMK pathway mediates LPS-induced mTOR activation, which
promotes TNF-α protein expression.

3.4. Discussion
The present study provides the first evidence that LPS negatively regulates
cardiac Na/K-ATPase activity via the PI3K/Rac1/NADPH oxidase pathway. Inhibition of
Na/K-ATPase activates mTOR apparently via Ca2+/CaMK, leading to TNF-α protein
production in cardiomyocytes. Na/K-ATPase/ Ca2+/CaMK /mTOR signaling represents a
novel molecular mechanism by which LPS stimulates cardiac TNF-α protein production
(Figure 3.8).
Na/K-ATPase is an important ion transporter and signal transducer located at the
cell membrane. It has been demonstrated that Na/K-ATPase activity is decreased during
the inflammatory response of the lung, kidney and innate immune system and contributes
to pro-inflammatory factor mRNA expression (Guzman et al. 1995; Koksel et al. 2006;
Ohmori et al. 1991). Here, we provided both in vivo and in vitro evidence to show that
LPS inhibits Na/K-ATPase activity in the heart. It is interesting to note that Na/KATPase inhibition enhances LPS-induced TNF-α protein production without any
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Figure 3.7. Role of Rac1, Na/K-ATPase and CaMK in LPS-induced mTOR activation in
cardiomyocytes. (A) WT neonatal cardiomyocytes cultured in serum free medium were
infected with Ad-Rac1N17 followed by LPS treatment (1 µg/ml) for 15 min. (B and C)
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Figure 3.8. Schematic diagram illustrates the involvement of Na/K-ATPase/mTOR
signaling pathways leading to cardiomyocyte TNF-α protein production during LPS
stimulation. LPS suppresses Na/K-ATPase activity via the PI3K/Rac1/NADPH oxidase
pathway in the myocardium. Inhibition of Na/K-ATPase activates mTOR via
Ca2+/CaMK. Activated mTOR promotes TNF-α protein production. TLR4, toll-like
receptor 4.
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apparent effects on TNF-α mRNA expression in cardiomyocytes. Since TNF-α mRNA
stability is not affected, these results suggest that inhibition of Na/K-ATPase may
promote TNF-α protein translation or inhibit its degradation in cardiomyocytes during
LPS stimulation.
Studies have shown that activation of NADPH oxidase inhibits Na/K-ATPase by
glutathionylation of its β subunit (Figtree et al. 2009). We have demonstrated previously
that LPS activates NADPH oxidase via PI3K/Rac1 signaling in cardiomyocytes (Zhang
et al. 2011 Chapter2). In agreement with this finding, the present study showed that the
reduction of myocardial Na/K-ATPase activity during LPS stimulation was prevented by
inhibition of PI3K, Rac1 or NADPH oxidase, indicating that activation of
PI3K/Rac1/NADPH oxidase pathway inhibits myocardial Na/K-ATPase activity during
endotoxemia.
It is well established that inhibition of Na/K-ATPase activity increases
intracellular Ca2+ via the Na+/Ca2+ exchange (Bers et al. 2006). We have previously
shown that intracellular Ca2+ levels are increased by LPS in cardiomyocytes and
contribute to TNF-α expression (Geoghegan-Morphet et al. 2007). To study the role of
Rac1, a negative regulator of Na/K-ATPase in Ca2+ homeostasis, we measured Ca2+
transients in cardiomyocytes and found that Rac1 deficient cardiomyocytes exhibited
significantly lower intracellular Ca2+ levels compared with Rac1f/f cells during basal
conditions and in response to LPS, suggesting that activation of Rac1 increases
intracellular Ca2+ via inhibition of Na/K-ATPase. CaMK is a downstream target of Ca2+
(Mendez-Samperio et al. 2006; Rosengart et al. 2000). Our study further demonstrated
that inhibition of CaMK decreased TNF-α expression during LPS stimulation. CaMK
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appears to affect both TNF-α protein and mRNA levels, which presumably reflects the
multiplicity of cellular effects triggered by this kinase. Taken together, our data suggest
that LPS activates Rac1/Ca2+/CaMK signaling leading to TNF-α protein expression.
Activation

of

mTOR

stimulates

global

protein

synthesis

by

directly

phosphorylating eukaryotic initiation factor 4E-binding protein (4E-BP) and in the longer
term increases levels of ribosomal proteins(Hay & Sonenberg 2004; Ruvinsky &
Meyuhas 2006). LPS activates mTOR in phagocytes (Baker et al. 2009; Haidinger et al.
2010; Weichhart et al. 2008), bone marrow cells (Chen et al. 2010) and HL-1 cells (a
cardiomyocyte cell line) (Song et al. 2010), however the role of mTOR in proinflammatory cytokine expression is cell type specific. For example, rapamycin, an
mTOR inhibitor decreased the production of pro-inflammatory cytokines such as IL-12
and TNF-α in dendritic cells (Haidinger et al. 2010). In contrast, rapamycin enhanced
LPS-induced TNF-α mRNA and protein levels in monocytes (Weichhart et al. 2008) and
macrophages (Baker et al. 2009). Similarly, overexpression of mTOR in HL-1 cells
decreased TNF-α protein levels stimulated by LPS (Song et al. 2010). In the present
study, we showed that mTOR was rapidly and transiently activated between 15 to 30
minutes after LPS stimulation in neonatal cardiomyocytes cultured in serum free
medium. Our data showed that Na/K-ATPase activity were decreased in the cells cultured
in medium contain 10% FBS after 2 hours of LPS stimulation. The mismatch between the
time points of Na/K-ATPase and mTOR activation is possibly due to different culture
conditions with and without serum. Rapamycin decreased TNF-α protein levels after LPS
stimulation but had no apparent effect on TNF-α mRNA expression or global protein
synthesis. Our data suggest that mTOR is important in LPS-induced TNF-α protein
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synthesis in cardiomyocytes.
mTOR activation is regulated by a number of factors including TSC1/TSC2 and
Ca2+ (Hay & Sonenberg 2004; Hoyer-Hansen et al. 2007; Lenz & Avruch 2005). The
relationship between intracellular Ca2+ concentrations and mTOR activity is cell-type
specific (Hoyer-Hansen et al. 2007; Lenz & Avruch 2005). In primary mouse neurons,
glutamateric stimulation activates mTOR in a Ca2+/CaMK-dependent manner (Lenz &
Avruch 2005). On the other hand, mTOR activity is inhibited by an increase in cytosolic
Ca2+ in MCF-7 breast cancer cells (Hoyer-Hansen et al. 2007). The present study showed
that LPS-induced inhibition of Na/K-ATPase activity increases intracellular Ca2+ in
cardiomyocytes. To study the role of CaMK, a downstream effector of Ca2+ in mTOR
activation, a selective inhibitor of CaMK was employed. Our data showed that inhibition
of CaMK decreased mTOR activity in response to LPS. Furthermore, LPS-induced
mTOR activity was blocked by inhibition of Rac1 but enhanced by the inhibition of
Na/K-ATPase. Our results suggest that Rac1 inhibits Na/K-ATPase and increases
Ca2+/CaMK activity, which subsequently activates mTOR and promotes TNF-α protein
translation in cardiomyocytes during LPS stimulation. In addition, our study also showed
that inhibition of CaMK blocked LPS-induced TNF-α mRNA and protein expression,
indicating that there are other parallel pathways through which Na/K-ATPase regulates
mTOR activation.
Interestingly, mTOR also promotes the translation of cellular mRNAs that have a
5’ terminal oligopyrimidine (TOP) tract adjacent to the cap site (Ruvinsky & Meyuhas
2006). The 5’TOP tracts, which are found in all mRNAs that encode ribosomal proteins,
enhance translation upon mTOR activation (Ruvinsky & Meyuhas 2006). Examination
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of the 5’ untranslated region of TNF-α mRNA reveals that both the mouse (GenBank:
U68414) and human (GenBank: NM_000594) forms contain a 5’ CTCCCTC sequence,
which conforms to the established consensus for regulatory 5’TOP motifs (Ruvinsky &
Meyuhas 2006). The presence of this putative 5’TOP motif further supports our
hypothesis that TNF-α is controlled at the translational level by mTOR in cardiomyocytes
during LPS stimulation.
In conclusion, our study demonstrated that LPS inhibits Na/K-ATPase activity via
PI3K/Rac1/NADPH oxidase pathway in the myocardium. Inhibition of Na/K-ATPase
activity promotes TNF-α protein production by Ca2+/CaMK-dependent mTOR activation
in cardiomyocytes. This Na/K-ATPase/ Ca2+/CaMK /mTOR pathway provides novel
insight into the signal transduction mechanisms that regulate myocardial TNF-α
expression, and may have therapeutic implications in the treatment of sepsis (Figure 3.8).
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Chapter 4. Rac1 regulates LPS-induced TNF-α expression and cardiac dysfunction
via MKP-1
4.1 Introduction
Sepsis is the 10th most common cause of death in the United States (Dellinger et
al. 2008). Cardiac dysfunction frequently accompanies severe sepsis and septic shock,
and is associated with a significant increase in mortality rate (70% to 90%) compared
with septic patients without cardiovascular impairment (20%) (Merx & Weber 2007).
Tumor necrosis factor-alpha (TNF-α) produced by cardiomyocytes is a major
contributing factor to cardiac dysfunction (Merx & Weber 2007; Parrillo et al. 1985).
However, the underlying molecular mechanisms regulating myocardial TNF-α
production during sepsis remain elusive.
Mitogen-activated protein kinases (MAPKs) including p38, ERK1/2, and JNK1/2
are key signaling molecules regulating inflammatory responses and the expression of proinflammatory cytokines (Dumitru et al. 2000; Kotlyarov et al. 1999). It has been
demonstrated that these MAPKs exhibit different effects on myocardial TNF-α
expression during endotoxemia (Peng et al. 2005b; Peng et al. 2003; Peng et al. 2009;
Rosengart et al. 2000; Thakur et al. 2006). Indeed, activation of ERK1/2 and p38
promotes TNF-α expression (Peng et al. 2005b; Peng et al. 2003; Rosengart et al. 2000;
Thakur et al. 2006). In contrast, we recently demonstrated that JNK1 decreases TNF-α
expression and improves cardiac function through inhibition of ERK1/2 and p38 activity
(Peng et al. 2009). However, the molecular mechanisms by which JNK inhibits ERK1/2
and p38 are not fully understood.
Inactivation of MAPKs is achieved primarily by MAPK phosphatases (MKPs)
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that dephosphorylate phosphothreonine and phosphotyrosine residues of MAPKs (Liu et
al. 2007). Studies have shown that MKP-1 negatively regulates the inflammatory
response of the innate immune system by accelerating MAPK inactivation and
attenuating the production of pro-inflammatory cytokines including TNF-α, interleukin
(IL)-1β and IL-6 in macrophages following LPS stimulation (Chen et al. 2002; Zhao et
al. 2006). Furthermore, deficiency in MKP-1 results in a significantly higher incidence of
mortality during endotoxemia, suggesting a protective role of MKP-1 in sepsis (Hammer
et al. 2006; Salojin et al. 2006; Zhao et al. 2006). MKP-1 is also expressed in
cardiomyocytes and is involved in cardiomyocyte apoptosis and cardiac hypertrophy
(Fischer et al. 1998; Kaiser et al. 2004; Palm-Leis et al. 2004). However, the role of
MKP-1 in myocardial TNF-α expression and cardiac dysfunction in endotoxemia
remains unknown.
MKP-1 has intrinsic phosphatase activity and is inducible in response to
extracellular stimuli. The mechanisms responsible for regulating MKP-1 expression are
cell type specific (Bokemeyer et al. 1996; Brondello et al. 1997; Li et al. 1999; SanchezTillo et al. 2007). For example, ERK1/2 (Brondello et al. 1997) and JNK (Bokemeyer et
al. 1996) are responsible for MKP-1 induction in fibroblasts while ERK, JNK1, and p38
are required for MKP-1 expression in macrophages (Ananieva et al. 2008; Chen et al.
2002; Kim et al. 2008; Sanchez-Tillo et al. 2007). Rac is necessary for cyclic strain
stress-induced MKP-1 expression in smooth muscle cells (Li et al. 1999). We have
demonstrated that Rac1 is a critical regulator of TNF-α expression and cardiac
dysfunction in endotoxemia (Zhang et al. 2011 Chapter 2). Interestingly, p21-activated
kinase (PAK), a serine-threonine protein kinase, acts as a downstream effector of Rac

111
(Molli et al. 2009). Furthermore, activation of the Rac1/PAK pathway increases proinflammatory factor expression in macrophages through JNK and p38 (Hsu et al. 2001).
PAK1 is the main PAK isoform in cardiomyocytes (Sheehan et al. 2007). The role of
PAK1 in TNF-α expression in cardiomyocytes has not been elucidated.
In the present study, we hypothesized that MKP-1 is induced during endotoxemia
via the Rac1/PAK1/JNK pathway in cardiomyocytes, leading to inhibition of TNF-α
expression and improvement of cardiac function in endotoxemia. To test this hypothesis,
cultured cardiomyocytes and MKP-1-/- mice were employed. Our results demonstrated for
the first time that MKP-1 represents an important negative feedback mechanism in
limiting pro-inflammatory response in the heart during endotoxemia.

4.2 Materials and methods
4.2.1 Animals and preparation of neonatal mouse cardiomyocytes
The investigation conforms to the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health (NIH Publication #85-23, revised
1996) and the experimental protocols were approved by the Animal Use Subcommittee at
the University of Western Ontario. C57BL/6 wild-type (WT), Rac1 floxed (Rac1f/f) and
JNK1-/- mice and were purchased from the Jackson Laboratory (Bar Harbor, Maine). Cre
transgenic mice (CreTG/+), which over-express Cre recombinase under the control of αmyosin heavy-chain (MHC) promoter, were provided by Dr. E. Dale Abel (University of
Utah, UT). The generation of cardiomyocyte-specific Rac1 knockout mice (Rac1CKO)
was achieved by breeding Rac1f/f mice with CreTG/+ mice as previously described (Rui et
al. 2005). MKP-1-/- mice were kindly provided by Bristol-Myers Squibb Pharmaceutical
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Research (Dorfman et al. 1996).
4.2.2 Isolation and culturing of neonatal mouse cardiomyocytes
The neonatal cardiomyocytes were prepared and cultured according to methods
we have previously described (Song et al. 2000; Chapter 2). Cells were treated with LPS
(Sigma, Oakville, Ontario, Canada), p21-activated kinases inhibitor III (IPA-3, EMD
Biosciences, San Diego, CA) and SP600125 (Enzo Life Sciences, Plymouth Meeting,
PA), infected with adenoviruses or transfected with small interfering RNAs (siRNAs).
4.2.3 Adenoviral infection of neonatal cardiomyocytes
Cardiomyocytes were infected with adenoviruses carrying a dominant-negative
form of Rac1 (Ad-Rac1N17, Vector Biolabs, Philadelphia, PA), or LacZ (Ad-LacZ,
Vector Biolabs, Philadelphia, PA) at a multiplicity of infection (MOI) of 10 plaque
forming units/cell. Adenovirus-mediated gene transfer was applied as previously
described (Peng et al. 2003; Chapter 2). All experiments were performed after 48 hours
of adenoviral infection.
4.2.4 siRNA transfection of neonatal cardiomyocytes
Cardiomyocytes were treated with murine PAK1 siRNA to knock down PAK1
expression (Santa Cruz Biotechnology Inc., Santa Cruz, CA). A scrambled siRNA (Santa
Cruz Biotechnology Inc.) was used as a control. The transfection was performed with
transfection reagent (Santa Cruz Biotechnology Inc.) according to the manufacturer’s
instructions. After transfection, cells were maintained in normal culture medium for
additional 48 hours before LPS treatment.
4.2.5 Measurement of TNF-α and MKP-1 mRNA
Total RNA was extracted from cardiomyocytes using the Trizol Reagent (Gibco-
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BRL) as per manufacturer's instructions. TNF-α mRNA levels were determined by realtime reverse-transcriptase polymerase chain reaction (RT-PCR) as as previously
described (Peng et al. 2003; Chapter 2). 28S rRNA was used as an internal control. The
primers were: TNF-α upstream 5′-CCG ATG GGT TGT ACC TTG TC-3′ and
downstream 5′-GGG CTG GGT AGA GAA TGG AT-3′; MKP-1 upstream 5′-GGA GAT
CCT GTC CTT CCT GTA-3′ and downstream 5′-CTG ATG TCT GCC TTG TGG TTG3′; 28S rRNA upstream 5’-TTG AAA ATC CGG GGG AGA G-3’ and downstream 5’ACA TTG TTC CAA CAT GCC AG-3’. Samples were amplied for 34 cycles using MJ
Research Opticon Real-time PCR machine. The levels of TNF-α and MKP-1 were
compared to that of 28S rRNA, and the relative expression of these genes was obtained.
4.2.6 Measurement of TNF-α protein
TNF-α protein levels were measured using a mouse TNF-α ELISA kit
(eBioscience, USA), according to the manufacturer’s instructions.
4.2.7 Western blot analysis
Ten to twenty micrograms of protein lysates were subjected to separation on a
10% SDS-PAGE gel, followed by electrotransfer to nitrocellulose membranes. Blots
were probed with specific antibodies against ERK1/2 (1:500), phospho-ERK1/2 (1:500),
p38 (1:500), phospho-p38 (1:500), JNK1/2 (1:500), phospho-JNK1/2 (1:500), PAK1
(1:1000) and phospho-PAK1 (1:500, Cell Signaling Technology, Danvers, MA), MKP-1
(1:1000, Upstate, Lake Placid, NY), α-actinin (1:2000) and GAPDH (1:2000, Santa Cruz
Biotechnology Inc.) followed by incubation with horseradish peroxidase-conjugated
secondary antibodies (1:3000, Santa Cruz Biotechnology, CA) respectively. Signals were
detected by chemiluminescence and quantified by densitometry.
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4.2.8 Isolated mouse heart preparations
Adult WT and MKP-1-/- mice (male, 10 weeks old) were treated with LPS (10
mg/kg, i.p.) or saline. After 4 hours, hearts were isolated and perfused in a Langendorff
system with Kreb’s-Henseleit buffer at 3 ml/min constant flow. The Kreb’s-Henseleit
buffer was kept at 37 °C and consistently bubbled with a mixture of 95% O2 and 5%
CO2. Myocardial function was detected as previously described (Zhang et al. 2011
Chapter 2).
4.2.9 Statistical analysis
Results are presented as mean ± SEM from at least three independent
experiments. Differences between two groups were analyzed by a standard Student t-test.
For multigroup comparisons, one or two-way ANOVA followed by Student-NewmanKeuls or Bonferroni post-test was performed. P < 0.05 was considered statistically
significant.

4.3 Results
4.3.1 LPS increases myocardial MKP-1 expression
To examine whether LPS regulates cardiac MKP-1 expression in cardiomyocytes,
we first measured MKP-1 protein levels in neonatal cardiomyocytes and found that
MKP1 protein was increased after 1 hour of LPS stimulation (Figure 4.1A). To verify
these in vitro results, WT mice were treated with LPS or saline for 1 and 1.5 hours.
Hearts were then harvested and myocardial MKP-1 mRNA and protein levels were
detected. Myocardial MKP-1 mRNA and protein levels were markedly increased after
LPS stimulation (Figure 4.1B & 4.1C). These data show that LPS promotes MKP-1

115
A

7

0

15

30

60

120 (min)

MKP-1
!-actinin
1.8

*

MKP-1/!-actinin

1.5
1.2
0.9
0.6
0.3
0.0

Control

7

15

30

120 (min)

60

B
MKP-1 mRNA/28S

0.18

*

0.12

0.06

0.00

C

Control

Control

LPS

LPS

MKP-1
GAPDH

MKP-1/GAPDH

0.4

*

0.3
0.2
0.1
0.0

Control

LPS

Figure 4.1. LPS induces MKP-1 expression in neonatal cardiomyocytes and in the adult
myocardium. (A) WT cardiomyocytes were cultured in serum free medium for 24 hours
and then treated with vehicle or LPS (1 µg/ml) for 7, 15, 30, 60 and 120 minutes. MKP-1
protein was detected by western blotting. Adult male WT mice were treated with LPS (4
mg/kg, i.p.) for 1 or 1.5 hours. MKP-1 mRNA (B) and protein (C) levels in the left
ventricular myocardium were measured. Data are means ± SEM from 3 - 4 mice or
independent experiments. *P<0.05 vs. control.
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expression in cardiomyocytes in vitro and in myocardium in vivo.
4.3.2 MKP-1 inhibits LPS-induced myocardial ERK1/2 and p38 activation
MKP-1 inactivates MAPKs by dephosphorylating phosphothreonine and
phosphotyrosine residues. To determine the role of MKP-1 in cardiac MAPK inactivation
after LPS stimulation, we examined myocardial ERK1/2 and p38 phosphorylation in WT
and MKP-1-/- mice. In response to LPS, ERK1/2 and p38 phosphorylation was induced in
both WT and MKP-1-/- myocardium. Phosphorylation of ERK1/2 was diminished in the
WT myocardium between 2 and 3 hours after LPS stimulation, but it was sustained in the
MKP-1-/- myocardium. Similarly, p38 phosphorylation was increased in the WT
myocardium between 1.5 and 3 hours after LPS stimulation. Importantly, p38
phosphorylation was significantly higher in MKP-1-/- than the WT myocardium (Figure
4.2). Thus, MKP-1 deficiency enhanced ERK1/2 and p38 phosphorylation, demonstrating
an important role for MKP-1 in reducing the levels of myocardial ERK1/2 and p38
activation after LPS stimulation.
4.3.3 MKP-1 attenuates myocardial TNF-α expression in endotoxemia
To investigate the role of MKP-1 in myocardial TNF-α expression and heart
function during endotoxemia in vivo, WT and MKP-1-/- mice were treated with vehicle or
LPS. Our data showed that LPS increased myocardial TNF-α expression in both WT and
MKP-1-/- mice. Compared with the WT group, MKP-1-/- mice exhibited significantly
higher TNF-α mRNAand protein levels (Figure 4.3). These results suggest that MKP-1
limits myocardial TNF-α expression in response to LPS.
4.3.4 MKP-1 improves cardiac function during endotoxemia
Cardiac function was determined using the Langendorff preparation after 4 hours
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Figure 4.3. TNF-α expression in WT and MKP-1-/- myocardium during endotoxemia.
TNF-α mRNA (A) and protein (B) levels in WT and MKP-1-/- heart tissues were
measured after 1 and 2 hours of LPS treatment (4 mg/kg, i.p.). Data are means ± SEM,
n=3 to 5 per group. ** P <0.01 vs. control, † P <0.05 vs. WT+LPS.
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of LPS in vivo treatment. The rates of contraction (+dF/dtmax) and relaxation (-dF/dtmin),
and heart work in LPS-treated hearts were reduced in both WT and MKP-1-/- mice
relative to vehicle-treated mice. Furthermore, compared with WT mice, rate of
contraction and relaxation and heart work were significantly lower in MKP-1-/- mice
(Figure 4.4), indicating that MKP-1 expression improves cardiac function during
endotoxemia.
4.3.5 LPS activates PAK1 in cardiomyocytes
Rac contributes to the induction of MKP-1 expression in smooth muscel cells (Li
et al. 1999). PAK is a downstream effector of Rac (Molli et al. 2009). Activation of PAK
promotes pro-inflammatory cytokine expression (Hsu et al. 2001). To assess the role of
PAK1 in cardiac MKP-1 and TNF-α expression during endotoxemia, we first examined
PAK1 activity after LPS stimulation. Neonatal cardiomyocytes isolated from WT mice
were treated with LPS (1 µg/ml) for 7, 15, 30 and 60 min. PAK1 phosphorylation in these
cells peaked at 15 min and then returned to control levels at 60 min (Figure 4.5A),
indicating that LPS activates PAK1 in cardiomyocytes.
4.3.6 PAK1 increases LPS-induced TNF-α expression
To elucidate the role of PAK1 in LPS-induced TNF-α expression, neonatal
cardiomyocytes were treated with IPA-3, an inhibitor of PAKs. IPA-3 (1–10 µM)
decreased LPS-induced TNF-α mRNA expression and TNF-α protein levels in a dosedependent manner (Figure 4.5B & 4.5C). These results were further verified by using
PAK1 siRNA. As shown in Figure 4.5D, PAK1 mRNA expression was decreased by
56% after PAK1 siRNA transfection. The inhibition of PAK1 expression was associated
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Figure 4.4. Cardiac function in WT and MKP-1-/- mice after 4 hours of LPS treatment
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with decreased TNF-α mRNA and protein levels (Figure 4.5E & 4.5F). These data
indicate that activation of PAK1 promotes cardiac TNF-α expression in response to LPS.
4.3.7 PI3K/Rac1 pathway mediates LPS-induced PAK1 activation
It is well known that PAK1 is activated by certain small GTPases such as Rac
(Molli et al. 2009). We have demonstrated that the PI3K/Rac1 pathway is activated by
LPS and critical for cardiac TNF-α expression during endotoxemia (Zhang et al. 2011
Chapter 2). To determine if PI3K acts as an upstream regulator of PAK1, the PI3K
inhibitor, LY294002, was employed. LY294002 significantly decreased PAK1
phosphorylation induced by LPS (Figure 4.6A). To determine the role of Rac1 on PAK1
activity, neonatal cardiomyocytes were infected with an adenovirus encoding a dominant
negative form of Rac1 gene (Ad-Rac1N17), which specifically inhibits Rac1 activity.
Overexpression of Rac1N17 inhibited PAK1 activity in response to LPS (Figure 4.6B).
Taken together, these data imply that LPS activates PAK1 via PI3K/Rac1 in
cardiomyocytes.
4.3.8 PAK1 mediates LPS-induced p38 and JNK phosphorylation
To determine whether PAK1 regulates p38, ERK1/2 and JNK phosphorylation,
neonatal cardiomyocytes were transfected with PAK1 siRNA. Interestingly, PAK1
siRNA blocked p38 and JNK phosphorylation in response to LPS, but did not show any
effect on ERK1/2 phosphorylation (Figure 4.7).
4.3.9 The Rac1/PAK1/JNK pathway mediates LPS-induced MKP-1 expression
To further explore the downstream effectors of the Rac1/PAK1/JNK pathway,
MKP-1 expression was studied. Overexpression of Rac1N17 in neonatal cardiomyocytes
significantly decreased MKP-1 protein levels (Figure 4.8A). This result was further

121
A

15

7

0

30

60 (min)

B

p-PAK1
0.12

Total PAK1

p-PAK1/Total PAK1

1.8

TNF- α mRNA/28s

**

*

1.5
1.2
0.9
0.6

0.09
0.06

††
0.03
0.00

0.3
0.0

Control

7

15

30

Control

LPS

LPS+IPA-3 (10µM)

60 (min)

LPS (1µg/ml)

D
TNF- α protein
(pg/5 ×105 cells)

300

**

**

0.002

**†

200

** †

100

PAK1 mRNA/28s

C

**

0.001

0
LPS (1µg/ml)
IPA-3

-

-

-

10

+
-

+

+

+

1

5

10 (µM)

0.000

Scramble

PAK1 siRNA

TNF- α mRNA/28S

0.03

**

0.02

††
0.01

0.00

Scramble PAK1 siRNA Scramble PAK1 siRNA

LPS

TNF-α protein (pg/5×105 cells)

F

E

400

*
*†

300
200
100
0

Scramble PAK1 siRNA Scramble PAK1 siRNA

LPS

Figure 4.5. PAK1 activity promotes LPS-induced TNF-α expression in neonatal
cardiomyocytes. (A) Cardiomyocytes isolated from WT mice were treated with vehicle or
LPS (1 µg/ml) for 7, 15, 30 and 60 minutes. PAK1 phosphorylation was measured by
western blotting. Cells were treated with IPA-3 with or without LPS (1µg/ml) for 3 or 5
hours. TNF-α mRNA (B) and TNF-α protein in culture medium (C) were measured by
real-time RT-PCR and ELISA, respectively. (D) WT cardiomyocytes were transfected
with scrambled or PAK1 siRNA. PAK1 mRNA expression in these cells were detected.
Cells, transfected with scrambled and PAK1 siRNA, were treated with LPS (1µg/ml) for
3 or 5 hours. TNF-α mRNA (E) and protein levels (F) were measured. Data are means ±
SEM from 3 - 4 independent experiments. *P<0.05, **P<0.01 vs. control; †P<0.05, ††
P<0.01 vs. LPS and Scramble+LPS.

122

A
Control

LPS

LPS+LY

P-PAK1
Total PAK1

p-PAK1/Total PAK1

2.0

**

1.5

††
1.0
0.5
0.0

Control

LPS

LPS+LY

B
LPS
Ad-LacZ Ad-LacZ Ad-Rac1N17
p-PAK1
Total PAK1

**

p-PAK/Total PAK

0.25
0.20
0.15

††

0.10
0.05
0.00

Ad-LacZ

Ad-LacZ

Ad-Rac1N17
LPS

Figure 4.6. PI3K and Rac1 activity increases LPS-induced PAK1 activation. (A) WT
neonatal cardiomyocytes were incubated with LPS (1 µg/ml, 15 min) with or without
LY294002 (LY). (B) Cells were infected with Ad-Rac1N17 followed by LPS treatment
(1 µg/ml) for 15 minutes. PAK1 phosphorylation in these cells was detected by western
blotting. Data are mean ± SEM from 3 independent experiments. **P <0.01 vs. control;
††P <0.01 vs. LPS or Ad-LacZ+LPS.

123
B

A
LPS
Scramble

LPS
Scramble

Scramble PAK1 siRNA

P-p38

p-JNK1/2

Total p38

Total JNK1/2

P-JNK1/2/Total JNK1/2

*

0.6

p-p38/Total p38

PAK1 siRNA

0.5

0.7

*†

0.5
0.4
0.3
0.2
0.1
0.0

Scramble

Scramble

PAK1 siRNA

†

0.3
0.2
0.1
0.0

Scramble

*

0.4

Scramble

Scramble

PAK1 siRNA
LPS

LPS

C
LPS
Scramble Scramble

PAK1 siRNA

P-ERK1/2

Total ERK1/2

p-ERK1/2/Total ERK1/2

0.8

*

*

0.6
0.4
0.2
0.0

Scramble

Scramble

PAK1 siRNA
LPS

Figure 4.7. Effect of PAK1 on LPS-induced p38, JNK1/2 and ERK1/2 activation in
neonatal cardiomyocytes. WT cardiomyocytes, transfected with scrambled and PAK1
siRNA, were treated with LPS (1 µg/ml) for 1 hour. P38 (A), JNK1/2 (B) and ERK1/2
(C) phosphorylation and were detected by western blotting. Data are mean ± SEM from 3
independent experiments. *P <0.05 vs. control; †P <0.05 vs. Scramble+LPS.

124

A

B

LPS
Ad-GFP

LPS

Ad-Rac1N17

Ad-GFP

Rac1f/f Rac1CKO Rac1f/f Rac1CKO

MKP-1

MKP-1

GAPDH

GAPDH

0.20

0.5

MKP-1/GAPDH

MKP-1/GAPDH

*
0.15

†

0.10
0.05
0.00

Ad-LacZ

Ad-LacZ

Rac1 f/f
Rac1 CKO

0.4
0.3

*†

0.2
0.1

Ad-Rac1N17

0.0

LPS

C

Scramble Scramble

Control

Control

PAK1 siRNA

GAPDH

GAPDH

**

0.6

**

0.3

MKP-1/GAPDH

0.4

††

0.2
0.1
0.0

Scramble

LPS LPS+IPA-3

MKP-1

MKP-1

MKP-1/GAPDH

LPS

D

LPS

0.5

*

Scramble

0.4

††

0.2

0.0

PAK1 siRNA

Control

LPS

LPS+IPA-3

LPS

Control

LPS

LPS+SP

MKP-1

WT

WT

JNK1-/-

!-actinin

0.8

MKP-1/α-actinin

LPS
JNK1-/-

MKP-1

!-actinin

WT

*

1.0

†

0.6
0.4
0.2
0.0

F

Control

LPS

LPS+SP

MKP-1/α -actinin

E

JNK1 -/-

**

0.8
0.6

††

0.4
0.2
0.0

Control

LPS

125
Figure 4.8. Effect of Rac1, PAK1 and JNK on LPS-induced MKP-1 expression. (A) WT
neonatal cardiomyocytes were infected with Ad-Rac1N17 followed by LPS treatment (1
µg/ml) for 1 hour. MKP-1 protein levels were detected by western blotting. (B) Adult
male Rac1f/f and Rac1CKO mice were treated with LPS (4 mg/kg, i.p. injection) for 1.5
hours. MKP-1 protein levels in the left ventricular myocardium were determined. (C) WT
cardiomyocytes were transfected with PAK1 siRNA followed by LPS treatment for 1
hour. Cells were incubated with LPS for 1 hour with or without IPA-3 (10µM, D) and
SP600125 (SP, 10µM, E). MKP-1 protein levels in these cells were detected. (F) Adult
male WT and JNK1-/- mice were treated with LPS (4 mg/kg, i.p. injection) for 1.5 hours.
MKP-1 protein levels in the left ventricular myocardium were determined. Data are mean
± SEM from 3 - 4 independent experiments. *P <0.05, **P <0.01 vs. control; †P <0.05,
††P <0.01 vs. LPS, Ad-LaZ +LPS, Scramble+LPS.
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confirmed in vivo. As shown in Figure 4.8B, LPS enhanced MKP-1 protein levels in
Rac1f/f but not in the Rac1CKO myocardium. To examine whether PAK1 mediates MKP-1
expression, cardiomyocytes were treated with IPA-3 or transfected with PAK1 siRNA.
LPS-induced MKP-1 protein expression was blocked by both IPA-3 and PAK1 siRNA
(Figure 4.8C & 4.8D). To determine if JNK is involved in regulating MKP-1 expression,
cardiomyocytes were treated with SP600125, an inhibitor of JNK. LPS-induced MKP-1
protein expression was significantly reduced by SP600125 (Figure 4.8E). To verify this
result in vivo, WT and JNK1-/- mice were treated with LPS (4 mg/kg, i.p.) or saline for
1.5 hours. LPS significantly increased myocardial MKP-1 protein levels in WT mice but
had no apparent effect in JNK1-/- mice (P<0.05, Figure 4.8F). Taken together, these data
indicate that the Rac1/PAK1/JNK pathway mediates LPS-induced MKP-1 expression.

4.4 Discussion
The present study would appear to demonstrate for the first time that myocardial
MKP-1 is induced by LPS via the PI3K/Rac1/PAK1/JNK pathway. Enhanced MKP-1
expression attenuates ERK1/2 and p38 phosphorylation, leading to inhibition of
myocardial TNF-α expression and improvement of cardiac function during endotoxemia.
MKP-1 is constitutively active, thus its phosphatase actvity depends on its protein
expression but does not rely on post-translational modifications such as phosphorylation
(Liu et al. 2007). MKP-1 dephosphorylates MAPKs and impedes their cellular functions.
Recent studies have shown that MKP-1 expression is up-regulated in macrophages in
response to LPS (Chen et al. 2002). Deficiency of MKP-1 enhances p38 and JNK
phosphorylation and pro-inflammatory cytokine production including TNF-α, IL-1β and
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IL-6 in macrophages (Chen et al. 2002; Zhao et al. 2006). Consistent with this notion,
MKP-1-/- mice exhibit significantly higher serum cytokine concentrations and higher
mortality rate after LPS stimulation (Hammer et al. 2006; Salojin et al. 2006; Zhao et al.
2006). In the present study, we showed that LPS induced myocardial MKP-1 expression.
Furthermore, MKP-1 deficiency enhanced myocardial ERK1/2 and p38 phosphorylation
and increased cardiac TNF-α expression. Most importantly, MKP-1 deficiency worsened
cardiac function during endotoxemia. Thus, both in vitro and in vivo evidence
demonstrated that LPS induces MKP-1 expression, which inhibits ERK1/2 and p38
activation and myocardial TNF-α expression, and improves cardiac function during
endotoxemia.
Rac is one of the factors that are responsible for MKP-1 expression (Li et al.
1999). We recently demonstrated that PI3K-mediated Rac1 activation promotes TNF-α
expression and cardiac dysfunction in endotoxemia (Zhang et al. 2011 Chapter 2). PAK
proteins are downstream effectors of Rac and regulate many cellular events including cell
motility, survival, proliferation and gene expression (Molli et al. 2009). PAK1 is the main
isoform of this enzyme in the myocardium and plays an important role in cardiac
contractility and hypertrophy (Sheehan et al. 2009; Sussman et al. 2000). Studies have
shown that PAK protein is activated and contributes to IL-1 expression through MAPKs
upon ligand stimulation in macrophages (Hsu et al. 2001). In the present study, LPS
enhanced PAK1 activity in cardiomyocytes. Inhibition of PAK1 activity by the
pharmacological inhibitor, IPA-3, or PAK1 expression by PAK1 siRNA decreased LPSinduced TNF-α expression in cardiomyocytes. Furthermore, inhibition of PI3K and Rac1
decreased PAK1 activity in response to LPS in cardiomyocytes. These results indicate
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that PI3K/Rac1-mediated PAK1 activation plays an essential role in LPS-induced TNF-α
expression in cardiomyocytes.
ERK1/2, p38 and JNK MAPKs are important signaling molecules regulating
TNF-α expression in cardiomyocytes (Peng et al. 2005b; Peng et al. 2003; Peng et al.
2009; Rosengart et al. 2000; Thakur et al. 2006). ERK1/2 and p38 are positive regulators
of TNF-α expression (Peng et al. 2005b; Peng et al. 2003; Rosengart et al. 2000; Thakur
et al. 2006). In contrast, JNK1 inhibits TNF-α expression via inactivating LPS-induced
ERK1/2 and p38 MAPKs (Peng et al. 2009). In the present study, inhibition of PAK1
activity blocked LPS-induced p38 and JNK phosphorylation. These results suggest that
PAK1 may have both stimulatory and inhibitory effects on LPS-induced TNF-α
expression in cardiomyocytes. Its activation on p38 promotes TNF-α expression. On the
other hand, PAK1-mediated JNK activation inhibits LPS-induced TNF-α expression.
To address the molecular mechanisms by which JNK inhibits LPS-induced TNFα expression, we studied the role of MKP-1 in this process. Studies have shown that
MAPKs are involved in regulating MKP-1 expression. For example, ERK1/2 and JNK
activation are responsible for MKP-1 induction in fibroblasts (Bokemeyer et al. 1996;
Brondello et al. 1997). However, the effects of ERK1/2, p38 and JNK on MKP-1
expression in macrophages are controversial. Several studies have showed that ERK1/2
and p38 are required for MKP-1 expression in macrophages (Ananieva et al. 2008; Chen
et al. 2002; Kim et al. 2008). On the other hand, Sanchez-Tillo et al. reported that JNK1
is necessary for MKP-1 expression in macrophages which consequently decreases
ERK1/2 and p38 phosphorylation levels (Sanchez-Tillo et al. 2007). In the present study
we demonstrated that LPS-induced MKP-1 production was blocked by the inhibition of
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Rac1, PAK1 and JNK1 in cardiomyocytes, suggesting that the Rac1/PAK1/JNK1
pathway is required for LPS-induced MKP-1 expression in cardiomyocytes. MKP-1
mediates the inhibitory effect of JNK1 on ERK1/2 and p38 activity. Therefore,
Rac1/PAK1/JNK1-mediated MKP-1 expression provides a key negative feedback
mechanism to limit myocardial TNF-α production and improve cardiac function during
endotoxemia.
In conclusion, the current study showed that PAK1 is activated by the PI3K/Rac1
pathway and increases p38 and JNK activity. PAK1 increases TNF-α expression via p38
activation in response to LPS. On the other hand, Rac1/PAK1/JNK1 pathway enhances
MKP-1 expression, which inactivates ERK1/2 and p38, limits TNF-α expression and
improves

cardiac

function

during

endotoxemia

(Figure

4.9).

Thus,

the

Rac1/PAK1/JNK1/MKP-1 signaling pathway represents a novel negative feedback
mechanism in regulating TNF-α expression and cardiac function in endotoxemia, and
may have therapeutic implications in the treatment of sepsis.
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Figure 4.9. Schematic of the MKP-1 signaling pathway regulating TNF-α expression and
cardiac function during LPS stimulation. PAK1 is activated by PI3K/Rac1 pathway and
increases P38 and JNK activity. PAK1 increases TNF-α expression via p38 activation in
response to LPS. On the contrary, Rac1/PAK1/JNK pathway enhances MKP-1
expression, which inactivates ERK1/2 and p38, limits TNF-α expression and improves
cardiac function during endotoxemia.
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Chapter 5 Discussion
5.1 Summary and major findings
The overall goal of this thesis was to investigate the role of Rac1 in myocardial
TNF-α expression and dysfunction during sepsis. Specifically, the activation of Rac1 and
its signaling in the regulation of myocardial TNF-α mRNA expression and protein
synthesis in endotoxemia were examined (see Figure 5.1).
In Chapter 2, the mechanisms of Rac1 activation in the heart and the role of Rac1
in cardiac dysfunction during endotoxemia were studied. The results showed that LPS
activates PI3K in cardiomyocytes both in vitro and in vivo. Furthermore, activated PI3K
is responsible for Rac1 activation. Rac1 activity is required for induction of myocardial
TNF-α expression by LPS. This effect of Rac1 on TNF-α expression is mediated by
NADPH oxidase and ERK1/2. Finally, using cardiac-specific Rac1 knockout mice, I
showed that Rac1 activation leads to myocardial depression during endotoxemia (Figure
5.1).
In Chapter 3, I discovered that Rac1 promotes cardiac TNF-α protein synthesis
via the Na/K-ATPase/mTOR pathway in endotoxemia. Previous studies have shown that
Na/K-ATPase activity is inhibited in macrophages (Ohmori et al. 1991), lung (Koksel et
al. 2006) and kidney (Guzman et al. 1995) by LPS. I showed for the first time that Na/KATPase activity in the myocardium is decreased during endotoxemia. The suppression of
myocardial Na/K-ATPase activity is mediated through PI3K/Rac1/NADPH oxidase
pathway. This finding is consistent with a previous recent study showing that NADPH
oxidase decreases Na/K-ATPase activity in cardiomyocytes by glutathionylating its β
subunit (Figtree et al. 2009). Inhibition of Na/K-ATPase has been shown to potentiate
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Figure 5.1. Schematic Rac1 signaling pathway regulating TNF-α expression and cardiac
function in endotoxemia. LPS activates Rac1 through PI3K. Activation of Rac1 increases
NADPH oxidase and ERK1/2 activity, leading to increased myocardial TNF-α mRNA
expression. Moreover, Rac1-containing NADPH oxidase inhibits Na/K-ATPase and
activates Ca2+/CaMK-dependent mTOR, causing enhanced TNF-α protein synthesis.
Another effector of Rac1 is PAK1. PAK1 increases TNF-α expression via p38 MAPK.
On the other hand, PAK1 promotes JNK1-dependent MKP-1 expression, which
inactivates ERK1/2 and p38 MAPK, reduces TNF-α expression and improves heart
function.
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LPS-induced cytokine expression in macrophages (Ohmori et al. 1991). A novel finding
from my study is that, in cardiomyocytes, reduction of Na/K-ATPase activity leads to
enhanced TNF-α protein levels in response to LPS without any measurable effect on
TNF-α mRNA expression or stability.
It has been demonstrated that inhibition of Na/K-ATPase activity increases
intracellular Ca2+ concentrations via the Na/Ca exchanger (Bers et al. 2006). Since Rac1
is a negative regulator of Na/K-ATPase, I measured Ca2+ transients in Rac1f/f and
Rac1CKO ventricular cardiomyocytes and found that Rac1CKO cardiomyocytes exhibited
significantly lower intracellular Ca2+ levels compared with Rac1f/f cells in basal
conditions and in response to LPS. It appears that Rac1-mediated Na/K-ATPase
inhibition increases intracellular Ca2+ concentrations during endotoxemia. mTOR is a
Ca2+ sensitive regulator of protein expression which does so by controlling mRNA
expression, translation initiation and elongation (Hay & Sonenberg 2004; Hoyer-Hansen
et al. 2007; Lenz & Avruch 2005). Results in Chapter 3 demonstrated that mTOR is
activated by LPS in cardiomyocytes and increases TNF-α protein levels without any
significant effect on TNF-α mRNA expression or stability. In addition, LPS-induced
mTOR activity was blocked by inhibition of Rac1 and CaMKs but enhanced by
inhibition of Na/K-ATPase. Taken together, these results provide the first evidence that
inhibition of Na/K-ATPase activates Ca2+/CaMK-dependent mTOR, which increases
TNF-α protein production in cardiomyocytes (Figure 5.1).
In the Chapter 4, I identified a negative feedback mechanism, which limits
myocardial TNF-α expression and improves heart function in endotoxemia. Recent
studies have demonstrated that MKP-1 is an important negative regulator of the
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inflammatory response of the innate immune system (Chen et al. 2002; Hammer et al.
2006; Salojin et al. 2006; Zhao et al. 2006). In Chapter 4, I found that LPS increased
MKP-1 expression in the myocardium. Deficiency in MKP-1 prolonged myocardial
ERK1/2 and p38 activities and increased cardiac TNF-α expression in response to LPS.
MKP-1-/- mice showed a further decrease in cardiac function during endotoxemia,
compared to the corresponding WT group. Taken together, these results imply that LPS
induces myocardial MKP-1 expression, which inhibits TNF-α expression and improves
heart function in endotoxemia.
PAK1 is a downstream effector of Rac1 (Molli et al. 2009) and increases proinflammatory factor expression in macrophages through MAPKs (Hsu et al. 2001). My
results showed that LPS activated PAK1 through PI3K/Rac1 in cardiomyocytes (Chapter
4), consistent with previous studies (Molli et al. 2009). Activated PAK1 increased p38
MAPK activity and promoted TNF-α expression in cardiomyocytes. Rac1 is necessary
for MKP-1 expression in smooth muscle cells (Li et al. 1999). I showed that Rac1/PAK1
activation increased JNK1 activity, which induced MKP-1 expression, leading to
decreased TNF-α expression in cardiomyocytes during LPS stimulation. Therefore, I
demonstrated for the first time that Rac1/PAK1/JNK1-mediated MKP-1 represents an
important negative feedback mechanism in limiting the pro-inflammatory response in the
heart during sepsis (Figure 5.1).
Therefore, results from these chapters provide insight into the molecular
mechanisms of myocardial Rac1 activation as well as the pathways through which Rac1
regulates TNF-α mRNA expression and protein production in myocardium and cardiac
dysfunction during endotoxemia.

These studies may increase our understanding of
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mechanisms that regulate myocardial TNF-α expression and cardiac function during
sepsis.

5.2 Clinical implications
The heart is a major organ that produces TNF-α in sepsis (Grandel et al. 2000;
Kapadia et al. 1995; Peng et al. 2003). High levels of TNF-α produced by
cardiomyocytes impair cardiac function via direct suppression of cardiac contractility, the
induction of myocardial apoptosis, and inflammatory response (Meldrum 1998).
Therefore, understanding the underlying mechanisms of myocardial TNF-α production
may lead to new therapeutic approaches. A novel finding reported in this thesis is that
Rac1 is a critical regulator of myocardial TNF-α production and cardiac dysfunction in
sepsis. PI3K-mediated Rac1 activation promotes LPS-induced TNF-α mRNA expression
and protein production through the NADPH oxidase/ERK, PAK1/p38 and Na/KATPase/mTOR pathways. Cardiomyocyte specific deletion of Rac1 decreased
myocardial TNF-α expression and improved cardiac function in endotoxemia. These
results suggest that Rac1 may represent a novel therapeutic target for inhibiting TNF-α
expression and improving myocardial function in sepsis.
In contrast to its pathogenic effects, Rac1 activation also triggers a negative
feedback mechanism to limit myocardial TNF-α production via MKP-1. Myocardial
TNF-α mRNA and protein levels in MKP1-/- mice were enhanced compared to WT mice
in endotoxemia, which was associated with a further decrease in cardiac function. These
results indicate that MKP-1 may protect the heart from sepsis-induced injuries. To this
end, future studies may test the hypothesis that cardiomyocyte specific overexpression of
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the MKP-1 gene improves cardiac function during sepsis. While cardiac specific
overexpression of MKP-1 may benefit the heart during sepsis, a recent study showed that
overexpression of MKP-1 in the hippocampus of nonstressed rats produces profound
depressive-like responses (Duric et al. 2010). Therefore, tissue specific overexpression of
MKP-1 is critical to developing MKP-1 as a treatment for sepsis in humans.

5.3 Study limitations
5.3.1 Use of mouse models to simulate human disease conditions
All of the studies presented in this thesis were done either in primary neonatal
cardiomyocytes or adult cardiomyocytes in vitro or in an endotoxemic mouse model in
vivo. Animal models have many advantages in studying signaling pathways. For
example, animal models allow for the control of experimental conditions, collection of
tissue samples and the manipulation of the genetic systems, which are difficult or not
ethical to do in humans. Furthermore, mice have relatively shorter gestation (20 days)
and maturation (2 months), which enable experiments to be carried out with sufficient
sample size in a reasonably short period of time. In addition, approximately 99% of all
mouse genes have a human homologue (Waterston et al. 2002).
This thesis utilized LPS to simulate human sepsis. LPS is an endotoxin produced
by Gram-negative bacteria and is effective in inducing a sepsis-like state in animal
models.

But it does not represent all sepsis-associated infections. It has been

demonstrated that 37.6% of the septic cases from 1979 through 2000 were caused by
Gram-negative bacterial infection, while the rest resulted from Gram-positive bacterial,
polymicrobial and fungi infections (Martin et al. 2003). In addition, clinical studies have
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shown that 49% of the infections originated in the respiratory system while 21% were
abdominal infection. Patients with abdominal infection are more likely to have septic
shock and early renal failure, whereas patients with respiratory infections more
commonly exhibit early alterations in neurological function (Volakli et al. 2010). To this
end, intraperitoneal injection of LPS has been shown to induce septic shock, renal
dysfunction and abnormalities in coagulation (Doi et al. 2009; Levy & Deutschman
2004). Therefore, the endotoxemic model induced by LPS provides an appropriate model
for studying many manifestations of sepsis.
5.3.2 Use of pharmacological inhibitors to delineate signaling pathways
In this thesis, the following pharmacological inhibitors were used: LY294002,
apocynin, U0126, ouabain, KN-93, rapamycin, IPA-3 and SP600125 to selectively inhibit
PI3K, NADPH oxidase, ERK1/2, Na/K-ATPase, CaMKs, mTOR, PAK1 and JNK1,
respectively. LY294002 inhibits PI3K activity via competitive inhibition of an ATP
binding site on the p85α subunit. At low dose, it specifically abolishes PI3K activity (IC50
= 1.40 µM) and does not inhibit other lipid and protein kinases such as PI4K, EGFR,
PKA, PKC, MAPKs, ATPase, diacylglycerol kinase or Src (Vlahos et al. 1994). Thus,
LY294002 is highly selective for PI3K and represents an excellent tool for studying
PI3K-dependent signaling in this thesis.
Apocynin (4'-hydroxy-3'-methoxy-acetophenone) is a cell-permeable, relatively
selective inhibitor of NADPH oxidase (IC50 value: 10 µM in human neutrophils). Once
inside the cell, apocynin reacts with ROS and peroxidase to form an apocynin radical,
which prevents the translocation of two essential cytosolic proteins, p47phox and p67phox to
the cell membrane and their binding with Nox2, thereby inhibiting the assembly of
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NADPH oxidase (Stefanska & Pawliczak 2008). Besides its ability to inhibit NADPHoxidase, apocynin also inhibits cytochrome P450 (IC50 value: 600 µM) (Pietersma et al.
1998), and thromboxane synthase (IC50 value: 1 µM- 0.1nM) (Engels et al. 1992).
Although, in this thesis, apocynin (400 µM) significantly decreased LPS-induced O2production in cardiomyocytes, the effects of apocynin on thromboxane synthase cannot
be excluded.
U0126 is a cell permeable, potent inhibitor of MEK1 and MEK2 (IC50 of 72 nM
and 58 nM, respectively), both of which activate ERK1/2 (Duncia et al. 1998). U0126
noncompetitively binds with the deltaN3-S218E/S222D site of MEK1/2 and inhibits
MEK1/2 activation (Favata et al. 1998). This compound also inhibits other kinases
including MKK-3/4/6, p38, PRAK and PKBα at 4-10 times higher IC50 concentrations
compared with its effect on MEK-1 (Davies et al. 2000; Favata et al. 1998). Although the
effect of U0126 on the above protein kinases cannot be completely ruled out, U0126 is
still a relatively specific inhibitor of MEK1/2.
Ouabain, a cardiac glycoside, is a specific inhibitor of Na/K-ATPase which dose
so by binding to a cavity formed by the transmembrane helices of the α subunit of Na/KATPase, thereby blocking ion transportation (Ogawa et al. 2009) or promoting the
interaction of Na/K-ATPase with signaling molecules, such as Src and MAPKs (Li & Xie
2009). Ouabain has no effect on the Mg2+-ATPase and the HCO3--ATPase (Knauf et al.
1976). Therefore, ouabain selectively inhibits Na/K-ATPase without any measureable
effect on other ATPases.
KN-93 is a potent and cell-permeable inhibitor of CaMKs by competitively
blocking calmodulin binding to the calmodulin-binding region of CaMK. It inhibits
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CaMK I (IC50 = 5 µM), CaMK II (IC50 = 1 µM) and CaMK IV (IC50 = 7 µM) (Means
2008). This compound does not affect the activities of PKA, PKC, MLCK, or Ca2+phosphodiesterase (Riganti et al. 2009). However, KN-93 shows inhibitory effects on
aminopyrine uptake in parietal cells (IC50 = 300 nM) (Mamiya et al. 1993) and voltagegated K+ channels in smooth muscle cells (IC50 = 270 nM) (Ledoux et al. 1999).
Interestingly, both Kv4.2 and Kv4.3 channels are substrates of CaMK II in
cardiomyocytes (Colinas et al. 2006) and the effects of KN-93 on K+ channels are a result
of CaMK II inhibition, making KN-93 a specific inhibitor of CaMKs in cardiomyocytes.
Rapamycin is a potent allosteric mTORC1 inhibitor by forming a complex with
the FK-binding protein 12 (FKBP12). This complex interacts with the multiprotein
complex composed of mTOR, mLST8, and raptor, leading to inhibition of mTORC1. A
recent study showed that prolonged rapamycin treatment (24 hours) reduces the levels of
mTORC2, which phosphorylates and activates Akt (Sarbassov et al. 2006). Rapamycin
has no significant inhibitory effect on other kinases (Davies et al. 2000). In the present
thesis, cells were treated with rapamycin for 3-5 hours. During this period of time, it
seems unlikely that rapamycin would have any nonspecific effect.
IPA-3 is a cell-permeable symmetrical disulfide allosteric inhibitor of group I
PAK activation, and 10 µM of IPA-3 inhibits PAK1, PAK2 and PAK3 activity by 90%,
70% and 60%, respectively. IPA-3 binds covalently to the PAK regulatory domain and
prevents binding to the upstream activator (Viaud & Peterson 2009). A recent study
showed that IPA-3 at 10µM inhibits PKBβ, FGR, GRK4, GSK3, p38α, PLK3 and SGK3
activity to 68%, 51%, 68%, 66%, 70%, 88% and 93% respectively (Deacon et al. 2008).
These nonspecific effects of IPA-3 cannot be ruled out in my thesis. To exclude these
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nonspecific effects, PAK1 siRNA was also employed to specifically inhibit PAK1
activity.
SP600125 is a potent, cell permeable inhibitor of JNK (IC50 = 40 nM for JNK-1
and JNK-2; 90 nM for JNK-3) (Bogoyevitch & Arthur 2008). It competes with ATP for
the ATP-binding site of JNK. Unlike ATP, SP600125 cannot be used in the
phosphotransfer reaction, thereby inhibiting JNK activity. This agent exhibits greater than
300-fold selectivity for JNK in relation to other MAPKs (ERK and p38) and PKA
(Bogoyevitch & Arthur 2008). This limitation of SP600125 cannot be ruled out in the
present thesis. To overcome this limitation, JNK1-/- mice were employed to confirm the
results of JNK inhibition by SP600125 in this thesis.

5.4 Future directions
Besides regulating TNF-α expression, it is possible that Rac1 contributes to
cardiac dysfunction in endotoxemia through other mechanisms that are not explored in
this thesis. Studies have shown that LPS increases caspase activation in the heart (Carlson
et al. 2005). Inhibition of caspase activity and transgenic overexpression of Bcl-2
improve myocardial function in endotoxemic mice, suggesting that cardiomyocyte
apoptosis may play a role in myocardial depression (Fauvel et al. 2001; Lancel et al.
2005). A recent study showed that Rac1 is required for cardiomyocyte apoptosis during
hyperglycemia (Shen et al. 2009). Therefore, one of the future studies of interest would
be to determine if Rac1 has any effect on cardiomyocyte apoptosis in endotoxemia.
Microcirculatory dysfunction plays an important role in the pathogenesis of sepsis
and is characterized by loss of vasomotor reactivity, endothelial cell injury, activation of
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coagulation, and disordered leukocyte trafficking (Trzeciak et al. 2008). The endothelium
is

known

to

dynamically

regulate

thrombosis,

profibrinolysis,

leukocyte

adhesion/migration, microvascular tone, permeability, and blood flow in both
physiological and pathophysiological conditions (Aird 2004). Numerous studies have
demonstrated that LPS enhances adhesion molecule and pro-inflammatory factor
expression in endothelial cells and endothelial permeability, leading to leukocyte
adhesion, migration and coagulation (Berman et al. 1993; Carlos & Harlan 1994;
McCuskey et al. 1996). Rac1 deficiency in endothelial cells prevents endothelial cell
migration, tubulogenesis, adhesion, and permeability in response to vascular endothelial
growth factor (VEGF) and sphingosine-1-phosphate (S1P) (Tan et al. 2008), indicating a
critical role of Rac1 in endothelial cell function. It would be interesting to investigate the
role of Rac1 in the microvascular circulation during sepsis.
In addition, in Chapter 3, I found that Rac1 deficiency decreased systolic Ca2+
concentration in cardiomyocytes through regulating Na/K-ATPase activity. Ca2+ has been
shown to be important in regulating cardiac contractility, hypertrophy, apoptosis, and
arrhythmia as well as gene expression (Erickson & Anderson 2008; Frey et al. 2000). It is
possible that Rac1 may regulate cardiac function in other pathophysiological conditions,
such as myocardial infarction. In this regarding, it is would be interesting to study the
role of Rac1 in cardiomyocyte apoptosis, arrhythmia, infarct healing and left ventricular
remodeling after myocardial infarction.

5.5 Conclusions
My studies provide strong evidence that Rac1 is a critical regulator of myocardial
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TNF-α expression and cardiac dysfunction in endotoxemia (Figure 5.1). LPS activates
Rac1 through PI3K. Activation of Rac1 increases NADPH oxidase and ERK1/2 activity,
leading to increased myocardial TNF-α mRNA expression (Chapter 2). Furthermore,
Rac1-containing NADPH oxidase inhibits Na/K-ATPase and activates Ca2+/CaMKdependent mTOR, resulting in enhanced TNF-α protein production (Chapter 3). These
effects of Rac1 on TNF-α expression lead to cardiac dysfunction in endotoxemia.
Another downstream effector of Rac1 is PAK1. PAK1 increases TNF-α expression via
p38 MAPK. On the other hand, PAK1 promotes JNK1-dependent MKP-1 expression,
which inactivates ERK1/2 and p38 MAPK, reduces TNF-α expression and improves
cardiac function. Rac1/MKP-1 pathway represents a negative feedback mechanism to
limit myocardial TNF-α expression and cardiac dysfunction in endotoxemia (Chapter 4).
These Rac1 pathways provide novel insights into the signal transduction mechanisms that
regulate myocardial TNF-α expression, and may have therapeutic implications in the
treatment of sepsis.
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